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ABSTRACT 
Orellanine (OR) is a nephrotoxic toxin produced by some mushroom species of the 
Cortinarius genus, typically found in Europe and North America. The nephrotoxicity of 
Cortinarius orellanus is well known and was first recognized in the 1950s when this 
mushroom was identified as the cause of a mass poisoning in Poland. This toxin induces 
an acute renal failure which can be very severe or even irreversible and fatal. The 
mechanism of toxicity is not yet fully understood, but it has been shown that the toxin 
inhibits the synthesis of proteins, RNA and DNA, and generates reactive oxygen species 
(ROS) and subsequent oxidative stress. Chemically, orellanine resembles the bipyridyl 
herbicides diquat and paraquat (PQ). PQ toxicity is specially severe in the lungs both due 
to its accumulation, against a concentration gradient, through the highly developed 
polyamine uptake system, and capacity to continuously generate ROS through a redox 
cycle involving PQ radicals and oxygen, leading to oxidative stress-related cell death and 
inflammation. In prior studies, it was demonstrated that therapeutic regimen with lysine 
acetylsalicylate (LAS) has a great potential to be considered in the hospital treatment of 
PQ poisonings. Indeed, it was observed a full survival in rats treated with PQ+LAS and the 
structural alterations in the lung, kidney, liver and jejune were considerably attenuated, 
specially concerning to collagen deposition. 
Due to the high toxic potential of OR and considering the absence of a specific 
antidote for this poisoning, the aim of this dissertation was to evaluate the potential 
protective effect of LAS. 
Animals were divided in four groups that were treated as follows: (1) control group, 
animals were subjected to two 0.9% saline solution administrations (0 and 4 h); (2) OR 
group, animals were exposed to one dose of OR (15 mg/kg) followed by one 0.9% saline 
solution 4 h after OR administration; (3) LAS group, animals were exposed to a 0.9% 
saline solution followed by one  dose of LAS (200 mg/kg) 4 h after saline administration; 
and (4) OR + LAS group, animals were exposed to one dose of OR (15 mg/kg) followed 
by one dose of LAS (200 mg/kg) 4 h later. Twenty-four hours after the last administration, 
all animals were anesthetized with xylazine/ketamine (10 and 100 mg/kg, respectively). All 
administrations were given intraperitoneally. Blood, urine and solid tissue samples (liver, 
kidneys, lungs, heart and spleen) were collected for subsequent biochemical analysis. 
A statistically significant increase of uric acid (UA) in OR group (1.14±0.39 mg/dL, 
p<0.05), when compared with control group (0.20±0.07 mg/dL), was registered. This 
increased UA was not observed in OR+LAS group (0.30±0.12 mg/dL). The increased UA 
in OR group can either be related to a possible kidney damage or to an increased 
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catabolism of purines. Indeed, OR caused notorious kidney damage, with tubular ectasia, 
tubular proteinosis, and epithelial cells of the affected tubules exhibited marked 
cytoplasmic degenerative changes or necrosis and apoptosis. The histological kidney 
findings also showed that LAS did not revert the damage caused by OR, being that, the 
volume of the affected tubules was apparently higher in the rats of OR+LAS group. The 
liver was also shown to be an organ affected by OR poisoning. Mild lobular inflammatory 
activity, parenchymal damage, hemorrhage and absence of viable hepatocytes were 
evident in animals treated with OR. The animals exposed to OR+LAS had livers with an 
apparent higher volume of lesions. The oxidative stress biomarker, GSSG, was markedly 
increased in OR+LAS group (0.76±0.24 and 14.93±1.60 U/L, p<0.01) when compared to 
control group (0.09±0.01 and 19.52±2.31 U/L) for kidney and liver, respectively. 
Accordingly, GSH/GSSG ratio suffered a significant reduction (0.58±0.23 (p<0.05) and 
1.138±0.3135 (p<0.0001)) compared to the control group (13.00±2.59 and 11.28±1.89). 
Taken together, these results demonstrate that LAS do not confer a protection against 
orellanine induced-toxicity and, in some organs, it seems to worsen injury. 
 
Keywords: Orellanine; lysine acetylsalicylate; kidney; liver; injury   
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RESUMO 
A orelanina (OR) é uma toxina nefrotóxica produzida por algumas espécies de 
cogumelos do género Cortinarius, que normalmente são encontrados na Europa e na 
América do Norte. A nefrotoxicidade do Cortinarius orellanus é bem conhecida desde 
1950, quando este cogumelo foi identificado como causa de um elevado número de 
intoxicações na Polónia. Esta toxina induz uma insuficiência renal aguda que pode ser 
muito grave ou mesmo irreversível e fatal. O mecanismo de toxicidade ainda não é 
totalmente compreendido, mas tem sido demostrado que esta toxina inibe a síntese de 
proteínas, RNA e DNA, gera espécies reativas de oxigénio (ROS) e consequente stress 
oxidativo. Quimicamente, a OR assemelha-se aos herbicidas bipiridílios diquato e 
paraquato (PQ). A toxicidade do PQ é essencialmente grave nos pulmões devido quer à 
sua acumulação, contra um gradiente de concentração, por meio de um sistema de 
captação de poliaminas, quer à sua capacidade para gerar continuamente ROS através 
de um ciclo redox que envolve radicas PQ e oxigénio, levando a uma situação de stress 
oxidativo, morte celular e inflamação. Em estudos anteriores, foi demonstrado que um 
regime terapêutico com acetilsalicilato de lisina (LAS) apresenta grande potencial para 
ser utilizado no tratamento hospitalar da intoxicação por PQ. De facto, foi observada uma 
total sobrevivência em todos os ratos tratados com PQ+LAS, sendo que as alterações 
estruturais no pulmão, rim, fígado e jejuno foram consideravelmente atenuadas, 
especialmente em relação à deposição de colagénio. 
Devido ao alto potencial tóxico da OR e considerando a inexistência de um antídoto 
específico para esta intoxicação, o objetivo deste trabalho foi avaliar o potencial efeito 
protetor do LAS. 
Os animais foram divididos em quatro grupos, tratados de acordo com o seguinte: (1) 
grupo controlo, os animais foram tratados às 0 e 4 horas com solução de soro fisiológico 
a 0.9%; (2) grupo OR, os animais foram expostos a uma dose de OR (15 mg/kg), seguida 
por uma dose de soro fisiológico a 0.9% 4h após a administração de OR; (3) grupo LAS, 
os animais foram tratados com soro fisiológico a 0.9%, seguido de uma dose de LAS (200 
mg/kg) 4h após a administração do soro; (4) grupo OR+LAS, os animais foram 
submetidos a uma dose de OR (15 mg/kg) seguida por uma dose de LAS (200 mg/kg) 4h 
após. 24 horas após a última administração, todos os animais foram anestesiados com 
xilazina e ketamina (10 e 100 mg/kg, respetivamente). Todas as administrações foram 
feitas por via intraperitoneal. Amostras de sangue, urina e tecidos (fígado, rins, pulmões, 
coração e baço) foram colhidas para subsequente análise bioquímica.  
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Foi observado um aumento estatisticamente significativo de ácido úrico (UA) no grupo 
OR (1.14±0,39 mg/dL, p<0.05), quando comparado com o grupo controlo (0,20±0,07 
mg/dL). Este aumento não foi observado no grupo OR+LAS (0,30±0,12 mg/dL). O 
aumento de UA no grupo OR pode estar relacionado com uma possível lesão renal ou 
com o aumento do catabolismo das purinas. De facto, a OR causou danos notórios nos 
rins, como ectasia tubular, proteinose tubular e as células epiteliais dos túbulos afetados 
exibiram alterações citoplasmáticas marcadas e degenerativas ou necrose e apoptose. 
Estes achados histológicos renais mostraram também que o LAS não reverteu o dano 
causado pela OR, sendo que o volume dos túbulos afetados foi aparentemente mais 
elevado nos ratos do grupo OR+LAS. O fígado também demonstrou ser um órgão 
afetado pela intoxicação com OR. Atividade inflamatória lobular, lesão parenquimatosa, 
hemorragia e ausência de hepatócitos viáveis foram evidentes nos animais tratados com 
OR. Os animais expostos a OR+LAS apresentaram fígados com um maior volume 
aparente de lesões. O biomarcador de stress oxidativo, GSSG, mostrou-se 
significativamente aumentado no grupo OR+LAS (0,76±0,24 e 14,93±1.60 U/L p<0.01) 
quando comparado com o grupo controlo (0,09±0,01 e 19,52±2.31 U/L) para o rim e 
fígado, respetivamente. Em conformidade, o rácio GSH/GSSG sofreu uma redução 
significativa (0,58±0,23  (p<0.05) e 1,14±0,31 (p<0.0001)) em comparação com o grupo 
controlo (13.00±2.59 e 11,28±1.89). 
No seu conjunto, estes resultados demonstram que o LAS não confere proteção 
contra a toxicidade induzida pela OR e que, em alguns órgãos, parece agravar as lesões. 
 
Palavras-chave: Orelanina; acetilsalicilato de lisina; rim; fígado; lesão.    
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1. INTRODUCTION  
 
1.1 Mushrooms poisoning 
 
Mushrooms are ubiquitous in nature. They are an important source of nutrition, are 
high in protein and essential amino acids and tend to be fat free, cholesterol free, and low 
in calories. However, certain varieties contain chemicals that can be highly toxic to 
humans (Berger and Guss, 2005). There are about 5000 mushrooms species, of which 
approximately 50 - 100 are known to be poisonous to humans, whereas only 200 to 300 
varieties have been clearly established to be safely edible (Barbato, 1993; Brent and 
Kulig, 1998; Bryson, 1996; Ellenhorn and Barceloux, 1997). 
Mushroom poisoning is a global phenomenon and can be a source of major mortality 
and morbidity. This poisoning in humans has been described since time immemorial, 
which has been witnessed by ancient writings like “Rigveda” (at least 3500 B.C.) and 
“Atharvaveda” (at least 1500 B. C.). The first written record about a fungus is the death 
from fungal poisoning, of a mother, daughter and two full grown sons, an event, which 
Euripides (456–450 B.C.) commemorated by an epigram (kumar Jha and Tripathi). 
Mushroom poisoning is usually the result of ingestion of wild mushrooms due to 
misidentification of a toxic mushroom as an edible species. More than 95% of mushroom 
poisoning incidences around the world occur due to misidentification (Duffy, 2008). 
Recently, incidence of mushroom poisoning is increasing as a result of the increasing 
popularity of wild mushroom consumption. The incidence is more frequent in Western 
Europe with 50-100 fatal cases reported annually. Likewise, the incidence is 0.005% in 
USA and 0.05% in Iran (Kavalci et al., 2010). 
Toxic mushrooms can be grouped based on their toxic components: Amanitins 
(Cyclopeptides), Gyromitrin (Monomethylhydrazine), Orellanine (OR), Muscarine, Ibotenic 
acid and Muscimol, Coprine, Psilocybin (psilocin) and Gastrointestinal irritants (Raut et al., 
2014). Diaz et al (2005) has reviewed and established the classification of mushroom 
poisoning based on the time of presentation and target organ systemic toxicity. With 
respect to the time of presentation, mushroom poisoning is categorized as early onset (<6 
hours), late onset (6-24 hours), or delayed onset (>1 day). Early-onset toxicities include 
several neurotoxic, gastrointestinal and allergic syndromes. Late-onset toxicities include 
hepatotoxic, accelerated nephrotoxic and erythromelalgia syndromes. Delayed-onset 
toxicities include delayed nephrotoxic, delayed neurotoxic and rhabdomyolytic syndromes 
(Diaz, 2005). 
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Accurate estimates of worldwide poison by OR-containing mushrooms are difficult to 
establish due to lack of case reporting in hospital emergency rooms. In Portugal there is 
only one retrospective analysis of 93 cases of mushroom poisoning admitted in ten 
Portuguese hospitals between 1990 and 2008. Of those poisonings 63.4% were attributed 
to amatoxins-containing mushrooms and 31.7% were attributed to gastrointestinal 
irritants-containing mushrooms (Brandão et al., 2011). In 2015 and 2014 were reported to 
the Poison Information Centers (CIAV) 31 and 49 cases for mushroom intoxications, 
respectively (data is required CIAV).  The Portuguese population is essentially 
mycophobic, and the picking and consumption of wild mushrooms is generally restricted 
to rural areas, and to a small number of species. This fact can limit cases of poisoning to a 
typology that is easily recognizable locally (Brandão et al., 2011). In USA, a total of 6275, 
6818, 6600, 6575 and 6474 mushrooms intoxications were reported to the national poison 
data system of the American Association of Poison Control Centers in 2010, 2011, 2012, 
2013 and 2014, respectively. Of these poisonings, 9, 8, 1 and 1 cases were attributed to 
OR intoxication in 2010, 2011, 2012 and 2013, respectively (Bronstein et al., 2012; 
Bronstein et al., 2011; Mowry et al., 2013; Mowry et al., 2014). From the above 
information it is clear that OR poisoning has emerged as a public health problem 
worldwide.  
 
 
1.2 Cortinarius species 
 
OR is a highly nephrotoxic toxin found in various mushrooms of the Cortinaceae 
family, genus Cortinarius and subgenus Leprocybe (Karlson-Stiber and Persson, 2003), 
including fool´s webcap (Cortinarius orellanus) and deadly webcap (Cortinarius rubellus 
formerly named Cortinarius speciosissimus or Cortinarius orellanoides) (Barceloux, 2008; 
Herrmann et al., 2012). 
Cortinarius species is the largest genus of fungi that forms mushrooms comprising 
over 250 species. These usually form mycorrhizae with trees and can be found in 
Northern Europe and in mountainous areas of Central Europe (Barceloux, 2008), as well 
as in Northern America at the end summer or autumn (Horn et al., 1997). Cortinarius 
rubellus species inhabit moist or west conifer forest, particularly in moist acidic soil 
(Barceloux, 2008). 
The genus Cortinarius has a variety of shapes, but the common features are a spider-
web lie veil, the “cortina”, connecting the margin of the cap to the stalk, particularly in 
young specimens (Figure 1(a)). As the mushroom ages, the cortina disappears, resulting 
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in almost indistinguishable remains of the Cortina (Figure 1(b)) (Barceloux, 2008). The 
genus is subdivided into a number of subgenera using cap and stipe features of dry or 
viscid and base of the stipe bulbous or non-bulbous. Added to these are pigmentary 
differences, microscopic cap features and differences in ultraviolet fluorescence (Duffy, 
2008). 
They also have an orange, purple, or greenish yellow-colored fruit bodies with 
characteristic rusty orange gills and a thick stalk with striae and bulbous base (Wornle et 
al., 2004). These are characterized by having a knob-like protuberance on the rust-to 
yellow-brown cap (2-12 cm/1-5 in) that is conical in shape on young species and more 
flattened on older specimens. The broad, elliptical spores yield a rust brown spore print. 
The cylindrical stalk is similar in color to the cap and stalk sometimes contains lemon 
yellow bands that represent the remains of Cortina (Barceloux, 2008). 
OR has been found to be the toxin responsible for the lethal toxicity of several species of 
Cortinarius mushrooms. Only some species of Cortinarius mushrooms, such as 
Cortinarius orellanus, C. rubellus (C. orellanoides, C. speciosissimus, C. rainierensis, C. 
henrici), C. brunneofulvus, C. splendens, C. cinnamomeus, C. atrovirens, C. venenous, C. 
gentilis and C. armillatus (Antkowiak and Gessner, 1985; Bresinky and Besl, 1990; Danel 
et al., 2001; Oubrahim et al., 1997; Shao et al., 2016) contain the nephrotoxin OR. 
The content of OR was determined in dried fungus, varying greatly depending both on 
the mushroom portion considered and Cortinarius species. The yield of OR in these 
species is usually reported as being approximately 2% of the dried mushroom; the content 
is slightly lower in C. speciosissimus (Prast et al., 1988). The analysis of C. orellanus and 
C. rubellus species showed that the content of toxin (expressed on dry weight basis) was 
9400 and 7800 mg/Kg in caps, 4,800 and 4,200 mg/Kg in stems, and 3100 and 900 
mg/Kg in spores, respectively. In mycorrhiza roots from C. rubellus, the OR content was 
300 mg/Kg (Koller et al., 2002). In another study, the OR content in dried fungus was 
found to be about 14000 mg/Kg in C. orellanus and 9000 mg/Kg in C. rubellus (Prast and 
Pfaller, 1988). 
 
 
1.2.1 Cortinarius orellanus 
 
C. orellanus (Figure 1 (c)) is a medium sized gill mushroom that is characterized by a 
domeshaped, dry, orange, red, brown-to-yellow, brown cap; thick, well-spaced, orange 
brown gills, and a dry, yellowish to reddish brown stalk that is tapered below with some 
veil fibrils on the surface. The body of the mushroom is whitish to yellowish. Species in 
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this group have rust brown spore prints and the spores are elliptic and distinctly 
ornamented (Judge et al., 2010). The cap is 3-8 cm across and stalk measures 3-9 cm 
long and 4-12mm thick. These mushrooms fluoresce blue ultraviolet light (Duffy, 2008). 
C. orellanus is rare in Scandinavia but more common on the continent of Europe. It 
grows preferably in deciduous forest (Holmdahl, 2001). 
 
 
1.2.2 Cortinarius speciossimus or rubellus 
 
C. speciossimus (Figure 1 (d)) is characterized by a cap rust brown to orange, often 
has a steeper and darer colored elevation at the top of the cap, and its surface is dry and 
slightly scaly. The cap diameter is typically 4-8 cm when fully expanded, and the margin is 
often slightly rolled down even in fully mature specimens. The gills are pale yellowish at 
first, becoming rusty brown as the spores mature (Philips, 2006). It has been claimed that 
both C.henrici (Figure 1 (e)) and C. rainierensis are identical to C. rubellus (Karlson-Stiber 
and Persson, 2003). 
C. speciosissimus is a boreal fungus of coniferous forests, being widely distributed in 
the northern areas of central Europe (i.e. Scandinavia, northern Scotland) and in the 
mountainous areas of central Europe. Its prevalence seems to have increased in the most 
recent decades in Sweden, specially on acid soils in the southwestern parts (Holmdahl, 
2001). 
 
Part I: Introduction 
 
 
 
6 
 
 
Figure 1. (a) Cortina; (b) Remains of cortina; (c) Cortinarius orellanus; (d) Cortinarius 
rubellus; (e) Cortinarius henrici; (f) Psilocybe semilanceata; and (g) Cantharellus cibarius. 
 
 
1.3 Orellanine 
1.3.1 Chemistry 
 
Table 1 presents chemical properties of OR. It is a bipyridine N-oxide (2,2’-bipyridine-
3,3’,4,4’-tetrahydroxy-1,1’-dioxide) that exists as two tautomers (Nilsson et al., 2008) 
(Figure 2). The more stable tautomer is the amine oxide form. OR is a colorless fine 
(a) (b) 
(c) (d) 
(e) (f) (g) 
Cortina 
Gills 
Remains of 
cortina  
Poitned protuberance 
Bulbous base 
Cap 
Stalk 
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crystalline and navy blue-fluorescing compound that is stable at 150-160ºC, decomposing 
slowly above this temperature and under UV light to the yellow nontoxic bipyridyl 
compound orelline by releasing oxygen. An explosive degradation occurs at temperatures 
over 267ºC (Antkowiak and Gessner, 1985). Cooking temperatures, freezing and drying 
do not reduce the orellanine content (Richard et al., 1988). OR is stable for many years in 
the intact mushroom (Schumacher and Hoiland, 1983). Figure 3 demonstrates the 
reduction of OR to the nontoxic compound, orelline, via the intermediate orellinine 
(Antkowiak and Gessner, 1985; Oubrahim et al., 1998; Rapior et al., 1989; Richard et al., 
1988). Orelline appears as bright yellow crystals and orellinine is almost colorless. The 
stereochemistry of OR was confirmed by X-ray crystallography (Cohen-Addad et al., 
1987). In crystal conformation, the planes of the two pyridyl rings are nearly perpendicular, 
making the molecule chiral. However, OR isolated from the mushroom is an optically 
inactive racemic mixture; this is probably due to the low rotational barrier to racemization 
(Konig et al., 1994). 
 
Table 1 – Chemical properties of orellanine. 
Molecular formula 
Molar mass 
C10H8N2O6 
252.2 g/mol 
37338-80-00 
1.777g/cm3 
834.6ºC at 760 mmHg 
458.6ºC 
125.5 kJ/mol 
131.8 Å2 
1.7 
56.6 cm3 
141.1 cm3 
22.4 ×10-24cm3 
86.8 dyne/cm 
- 0.53 
- 1.2 
- 9.3 
- 3 
CAS number 
Density  
Boiling Point 
Flash Point 
Enthalpy of Vaporization 
Polar Surface Area 
Index  of Refraction  
Molar Refractivity 
Molar Volume 
Polarizability 
Surface Tension 
log P 
log P 
pKa (Strongest Acidic) 
pKa (Strongest Basic) 
 
In 1962, Grzymala (Grzymala, 1962) was the first to demonstrate experimentally 
the nephrotoxicity of C. orellanus and was the first to isolate OR on biological analysis. 
Dehmlow and Schulz (1985) were the first reporting the successful synthesis of OR 
and orelline (Dehmlow and Schulz, 1985). OR was synthesized in nine steps from 3-
amino pyridine. Orelline has also been synthesized from 2-bromo-3-hydroxypyridine 
(Hasseberg and Gerlach, 1988). 
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As referred, when placed under UV light, OR is, at first, navy blue fluorescent, and 
after several minutes shifts to bright turquoise fluorescent due to a rapid 
photochemical reaction (Antkowiak and Gessner, 1975). This photochemical 
decomposition has been shown to proceed by stepwise loss of the N-oxides to give, 
first, the mono N-oxide orellinine and, subsequently, orelline (Antkowiak and Gessner, 
1985). 
OR, orellinine and orelline are soluble in dilute sodium hydroxide, ammonium 
hydroxide and dimethyl sulfoxide (DMSO), slightly soluble in methanol, and practically 
insoluble in most organic solvents and water (Antkowiak and Gessner, 1979; 
Schumacher and Hoiland, 1983). OR, contrary to orelline, is well soluble in alkaline 
solutions. 
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Figure 2. Chemical structures of orellanine, orellinine and orelline. 
1.3.2 Toxicokinetics 
Little is known about the toxicokinetics of OR in humans, specially during the first 24 
hours after ingestion (Ojanperã, 2008; Prast and Pfaller, 1988). In animal studies, kidneys 
excrete detectable quantities of OR only for the first 24 hours after exposure (Prast and 
Pfaller, 1988).  This is consistent with observations in human cases of OR poisoning, 
where the toxin is not detected in urine samples collected from 2 to 18 days after ingestion 
(Dickman and Grollman, 2010; Rohrmoser et al., 1997). Typically, clinical samples are not 
obtained until several days after ingestion, due to the delayed onset of symptoms. Indeed, 
this has led to misdiagnosis of the poisoning, since the victim often does not associate the 
symptoms with a meal taken several days before. For this reason, no information is 
available regarding human plasma levels of OR attained shortly after exposure (Dickman 
and Grollman, 2010). 
Based on ingestion of a toxic dose of 100-200 g of mushrooms containing 0.1% OR, 
and assuming complete absorption and full plasma distribution, maximal peak plasma 
levels of the toxin is expected to range from 130 to 260 µmol/L (Grzymala, 1957; Koller et 
al., 2002). Based on limited testing, the clearance of OR from the blood is probably rapid 
(i.e., < 2-3 days) (Karlson-Stiber and Persson, 2003). 
The continued presence of OR in renal cortex after hemodialysis, and its persistent 
presence in this tissue for several months in the absence of detectable OR in urine or 
blood, suggests that the toxin is sequestered in the kidney in a poorly exchangeable form 
(Dickman and Grollman, 2010). 
 
1.3.3 Toxic doses 
Table 2 resumes the toxic doses of OR and dried Cortinarius homogenates for 
different species. The LD 50 has been determined in different animals and by different 
routes. Several studies on the toxicity of C. rubellus in rats were carried out by Nieminen 
and collaborators (Mottonen et al., 1975; Nieminen, 1976; Nieminen and Pyy, 1976a). 
Authors have shown that rats appear to be resistant to Cortinarius poisoning and a 
genetic variability was suggested since females were more resistant (Nieminen et al., 
1976). In another study (Nieminen and Pyy, 1976b), 23% of the animals showed total 
resistance to toxins, irrespective of dose, whereas in others the observed renal lesions 
were dose-dependent. 
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Table 2. Toxicity of orellanine and dried Cortinarius homogenates. Adapted from the work 
by Lampe et al. (Lampe, 1991). 
Toxin Species Route  LD50 LD100 Remarks 
OR 
Mouse 
SC 8.3 mg/Kg   
PO 33 mg/Kg 109 mg/Kg 
Male and female 
mice 
PO 90 mg/Kg   
IP 15 mg/Kg 42 mg/kg 
Male and female 
mice 
IP 12.5 mg/Kg   
Cat PO 8.3 mg/Kg   
Guinea 
pig 
IP 8 mg/Kg   
C.orellanus 
Mouse 
PO 2.2 g/Kg 4.57 g/Kg 
Containing 14 mg/g 
orellanine; male 
mice 
Containing 15-20 
mg/Kg orellanine; 
female mice 
Containing 15-
20mg/g orellanine; 
male rats 
PO 2.1 g/Kg   
Rat PO 0.976 g/Kg   
C.rubellus Mouse PO 3.12 g/Kg 6.22 g/Kg 
Containing 9 mg/g 
orellanine; male 
mice 
SC: subcutaneo; PO: per or;IP: intraperitoneal; LD50: medianl ethal dose; LD100:absolute lethal dose 
 
 
Clinical data indicates that humans appear to be more sensitive to toxic effects than 
mice and rats. The ingestion of only two to three mushrooms (3 mg of toxin which 
corresponds to 0.04 mg/kg for a human of 70 kg) seems to be enough to make the victim 
dependent on dialysis for the entire life (Calvino et al., 1998; Delpech et al., 1990). 
Similarly, in humans, the greater susceptibility of males to Cortinarius toxicity has been 
described by several authors (Danel et al., 2001; Short et al., 1980). Herrmann and 
colleagues (Herrmann et al., 2012) described a lethal dose of fresh C. rubellus between 
29 and 227 g for humans weighting about 70 kg. 
 
 
1.3.4 Mechanism of toxicity 
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OR and orellinine have similar toxicity, but orelline proved to be nontoxic (Spoerke, 
2000). The mechanism of toxicity is not yet fully understood. It was shown that the toxin 
inhibits the synthesis of macromolecules such as proteins, ribonucleic acid (RNA) and 
deoxyribonucleic acid  (DNA) (Danel et al., 2001; Karlson-Stiber and Persson, 2003; 
Richard et al., 1991); promotes a noncompetitive inhibition of the activity of alkaline 
phosphatase, γ-glutamyl transpeptidase and leucine aminopeptidase (Ruedl et al., 1989); 
and  interrupts the production of adenosine triphosphatase (Spoerke and Rumack, 1994),  
namely at the proximal tubular brush border, compromising utilization and reabsorption of 
peptides, polysaccharides and other molecules. 
Moser (Moser, 1969) showed that C. orellanus toxin inhibits DNA-depended activity of 
RNA polymerase B from rat liver (eukaryotic cell) and DNA-depended activity of RNA 
polymerase from Escherichia coli (prokaryotic cell). Later, Richard and co-authors 
(Richard et al., 1991) pretreated rat liver microsomes with OR and then exposed rabbit 
reticulocyte lysate to this mixture. It was observed the inhibition of protein synthesis, while 
direct addition of untreated OR or only microsomes did not. This suggests that inhibition of 
protein synthesis is due to a metabolite of OR. 
Orellanine inhibits pinocytosis in Amoeba proteus and inhibits growing of both slime 
mold  Discyostelium discoideu and Escherichia coli at 80 µM (Spoerke and Rumack, 
1994). The large spectrum of toxic effects in plants, animals and microorganisms 
suggests that the target is likely to be a cellular process found in both prokaryotes and 
eukaryotes (Richard et al., 1988). 
Rapidor and co-authors (Rapior et al., 1988) suggested that the Cortinarius toxicity is 
caused by metabolites with the isoxazolium core derived from the photochemical 
rearrangement of orellanine (called the phototoxicity mechanism of OR). In accordance, 
authors found that OR purified in the dark and administered to laboratory animals show 
low toxicity, while the one extracted in the light induces a toxic response (Figure 3). These 
intermediates can bind covalently with numerous proteins in the body, leading to organ 
damage. 
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Figure 3. Phototoxicity mechanism of orellanine.  
 
As already referred, OR chemically resembles the pyridine herbicides diquat (1,1’-
ethylene- 2,2’-bipyridinium) and PQ (1,1’-dimethyl-4,4'-bipyridinium) (Figure 4), and some 
authors suggested a possible mono-electronic reduction mechanism (generation of a 
stable radical) for its toxicity mechanism (Richard et al., 1995; Schumacher and Hoiland, 
1983). The consequence is obvious: production of free radicals and, therefore, oxidative 
stress similarly to PQ (Dinis-Oliveira et al., 2008; Dinis-Oliveira et al., 2009b). In opposite 
to PQ, this proposed intracellular toxic mechanism with NADPH plus H+ depletion would 
need a long time to impoverish the cells to the degree of inevitable necrosis, according 
with the delayed toxic effects observed in this type of mushroom poisoning (Deshpande, 
2002). 
hʋ hʋ hʋ hʋ
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Figure 4. Chemical structures of paraquat, diquat and orellanine. 
 
However, this model has been criticized since OR has a much more negative redox 
potential than PQ  and diquat (Cantin et al., 1988; Richard et al., 1997). Noteworthy, it 
was observed the formation of a radical form of OR by near UV (370 nm) at physiological 
pH under aerobic or anaerobic conditions (Richard et al., 1997). This apparently stable 
radical, identified as ortho-semiquinone anion radical (Figure 5), was also generated using 
biological oxidizing agents (e.g., cytochrome c and nicotinamide adenine dinucleotide) or 
enzymatic systems such as tyrosinase/oxygen (O2) and peroxidase/hydrogen peroxide 
(H2O2) (Oubrahim et al., 1998; Richard et al., 1995). Indeed, it is the ortho-semiquinone 
anion radical the responsible for superoxide radical production. At the renal spot of 
bioaccumulation of the toxin, a quickly change of small portions of OR rapidly cycling from 
its oxidized to its reduced form, might be sufficient to support continuous production of 
oxygen free radicals, which will induce oxidative stress. This process may lead to a large 
oxygen consumption, which might create hypoxic conditions, as well as the dramatic 
depletion of renal glutathione and ascorbate levels, consequently making cells more 
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susceptible to oxidant damage (Cantin et al., 1988; Oubrahim et al., 1998; Richard et al., 
1995). Corroborating this hypothesis, OR-treated animals did experience increased 
oxidative stress which is indicated by increasing of both plasma levels of ascorbyl radicals 
and protein oxidation in renal tissue (Nilsson et al., 2008).  
 
Figure 5. Redox cycling of orellanine. 
 
Oubrahim and colleagues (1997) proved the formation of a characteristic ortho-
semiquinone radical anion (SQ˙) derived from OR in a system containing horseradish 
peroxidase and H2O2. Since peroxidative oxidation proceeds via two one-electron 
oxidation steps, this enzyme can oxidize two molecules of OR to the corresponding 
semiquinone during one enzymatic cycle, or one molecule of orellanine to the 
corresponding quinone by two successive monoelectronic oxidation steps. The ortho-
semiquinone form of OR was also generated by the enzymatic system tyrosinase/O2 
which proceeds via a two-electron oxidation. In this case, the generation of the ortho-
semiquinone radical likely occurs as a result of an equilibrium between OR and its 
corresponding quinone. During oxidation of OR in renal tissue, ortho-semiquinone likely 
accumulates, whatever the mode of enzymatic oxidation may be (one or two electrons). 
The ortho-semiquinone, as well as the quinone, could participate in a variety of reactions 
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including covalent binding to biological compounds, leading to cell damage. In addition, 
when oxidation of orellanine by horseradish peroxidase/H2O2 occurred in presence of 
reducing agents of biological interest, such as ascorbic acid or glutathione, the formation 
of ascorbyl or glutathionyl radicals was observed (Oubrahim et al., 1997). 
Although all authors agree that OR is the main toxin, Cortinarius species also contain 
cyclic decapeptides (cortinarin A, B and C) that produce renal damage (Caddy et al., 
1982; Tebbett and Caddy, 1984). Cortinarin A and B (not C) were found to be nephrotoxic 
in animal studies (Tebbett and Caddy, 1984), but the role of these decapeptides in 
causing the Orellanus syndrome, or even their existence, have been questioned by 
several authors (Matthies and Laatsch, 1991). 
 
1.4 Poisoning orellanine 
1.4.1 Epidemiological studies 
 
OR poisoning is extremely serious. Until today orellanine poisoning has occurred in 
most parts of the European continent, Britain, North America, Canada and Australia 
(Bednarova et al., 1999; Danel et al., 2001; Esposito et al., 2015; Moore et al., 1991; 
Mount et al., 2002; Raff et al., 1992). 
Intoxication with the fungus C. orellanus has been described in literature. The toxicity 
of the mushroom C. orellanus was firstly discovered in 1957 when 136 habitants of 
Bygdosz (Poland) were intoxicated, which resulted in 23 deaths (Grzymala, 1957; 1959b; 
1962; Grzymala, 1965a; Grzymala, 1965b; Wysocki et al., 1958). C. orellanus 
intoxications are reported from Switzerland (Favre et al., 1976), France (Andary et al., 
1989; Bouget et al., 1990; Brousse et al., 1981; Delpech et al., 1990; Marichal et al., 1977; 
Rapior et al., 1989), Germany (Eigler et al., 1997; Farber and Feldmeier, 1977), 
Czechoslovakia (Bednarova et al., 1999; Bouska et al., 1979; Stredova et al., 1978), 
Bulgaria, Austria (Franz et al., 1996; Horn et al., 1997; Kerschbaum et al., 2012; 
Rohrmoser et al., 1997), Spain (Calvino et al., 1998), England (Kilner et al., 1999), Italy 
(Montoli et al., 1999) and U.S.A. (Moore et al., 1991). 
In 1974, four cases of poisoning by C. rubellus occurred in Finland (Hulmi et al., 
1974), followed by five cases in 1992 (Tidman and Sjostrom, 1992). Further incidents 
were reported in Scotland (Short et al., 1980; Watling, 1982), Sweden (Holmdahl and 
Blohme, 1995; Holmdahl et al., 1984), Norway (Fauchald and Westlie, 1982; Jacobsen et 
al., 1981), Italy (Busnach et al., 1983; C. et al., 1984), Germany (Nolte et al., 1987), 
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France (Traverso, 1973) and United Kingdom (Nagaraja et al., 2012), Scotland (Short et 
al., 1980) and Austria (Franz et al., 1996; Holzl et al., 1997; Kerschbaum et al., 2012). 
Intoxications by a further species, C. splendens, has been described in France (A., 
1981; Colon et al., 1981; 1982) and Switzerland (Schliessbach et al., 1983). 
Nephrotoxic Cortinarius species are morphological similar to mushrooms from 
psilocybe genus (Psilocybe semilanceata) (Figure 1 (f)), leading to mistake by 
inexperienced hallucinogenic mushrooms hunters (Franz et al., 1996). Likewise, 
misidentification of C. orellanus as Cantharellus cibarius (Figure 1(g)) and Cantharellus 
tubaeformis also occurs (Barceloux, 2008; Horn et al., 1997). It can be concluded that 
cases of orellanine poisoning are due to a lack of knowledge of mushroom species. This 
fact has led to several cases of accidental intoxication (Franz et al., 1996). 
 
1.4.2 Prognosis 
 
The chance of full recovery from OR poisoning depends on the amount of ingested 
toxin, age and general health of the individual patient, probably preexisting subclinical 
renal disease, and the time at which therapy is started (Horn et al., 1997). 
Grzymala (1959 and 1965) established a relationship between the duration of the 
latent period and poisoning severity (Grzymala, 1959a) (Gryzmala, 1965; Grzymala, 
1965b) . In his series, the latent period was: 
a) 10-17 days in patients presenting with thirst, burning sensation in the mouth and 
polyuria (mild intoxication); 
b) 6-10 days in patients presenting with digestive disorders, polyuria or oliguria, hematuria 
and leucocyturia, but no significant renal impairment; 
c) 2-3 days in patients with acute renal failure and death rate of about 50%. 
A short latent period indicates more severe poisoning. However, the rather variable 
individual response to orellanine poisoning makes an assessment of outcome difficult. 
Draffan and colleagues (Draffan et al., 1977) developed a method to measure 
bipyridines in plasma, being possible to get an exact measurement of the OR content in 
plasma. This method can give a good indication of the severity of poisoning, and also be a 
guide for a better treatment (Schumacher and Hoiland, 1983). 
Holdmdahl (2001) proposed a method for estimating the prognosis in individual cases. 
This method is called the “Cortinarius nephron toxicity prognostic index (CNT)” and is 
based on two parameters general available. The parameters used are the serum 
creatinine level before treatment and the former days after ingestion of the mushrooms. It 
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is calculated from the formula CNT=(𝑦 + 316) 𝑋 × 104 ⁄ ), where 𝑦 is the serum creatinine 
and 𝑋 the number of elapsed days. CNT index < 1.1 indicates a good prognosis; CNT 
between 1.1 and 2.1 indicates “intermediate” prognosis (probably chronic renal failure with 
serum creatinine higher than 200 µmol/L) and > 2.1 a poor outcome with end-stage renal 
failure requiring renal replacement therapy (Holmdahl, 2001). 
 
 
1.4.3 Diagnosis 
 
The diagnosis of OR poisoning can be clinical, mycological or toxicological (Herrmann 
et al., 2012; Rapior et al., 1989; Wornle et al., 2004). 
 
1.4.3.1 Clinical diagnosis 
 
OR poisoning is characterized by a long latent period. Typically, the onset of 
symptoms is delayed from 2-4 to 14 days after ingestion (Danel et al., 2001). The higher 
the quantity of mushrooms consumed, the shorter the latent period (Lampe, 1991). There 
is a significant variation on individual responses to poisoning, with the degree of renal 
injury ranging from mild and transient to severe and irreversible (Dickman and Grollman, 
2010). 
Some patients suffer mild gastrointestinal discomfort in the latency period before 
developing signs of renal impairment. Table 3 resumes signs, symptoms and analytical 
findings related to OR poisoning. The gastrointestinal phase (also known as prerenal 
phase) is primarily characterized by vomiting and nausea, and, less often, abdominal pain, 
asthenia, chills, burning sensation in the mouth, thirst, headache, myalgia, anorexia and 
diarrhea (Danel et al., 2001; Holmdahl and Blohme, 1995; Karlson-Stiber and Persson, 
2003; Schumacher and Hoiland, 1983). 
 
Table 3 – Signs, symptoms and analytical findings in intoxications by orellanine.  
Prerenal phase 
Vomiting, polydipsia, lumbar pain, nausea, abdominal pain, headache, polyuria, 
asthenia, diarrhea, anorexia, myalgia, faintness, paresthesia, constipation, chills, 
somnolence, vertigo, dysgeusia, sweats, tinnitus, burning in mouth, fatigue, thirst, dry 
mouth, visual defects, lumbar pain 
Renal phase 
Myalgia, intense lumbar pain, flank pain, oliguria, leukocyturia, hematuria, proteinuria, 
anuria, glycosuria, leukocytosis, increased serum creatinine, potassium and urea, 
renal histopathological analysis evidencing tubule-interstitial nephritis, interstitial 
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edema, inflammatory infiltrates and fibrosis/sclerosis 
Treatment 
Hemodialysis/peritoneal dialysis, extracorporeal hemoperfusion, plasmapheresis, 
corticosteroids, diltiazem, dopamine, selenium N-acetylcysteine and renal transplant 
 
Clinical signs may spontaneously disappear in some patients, leaving the poisoning 
unnoticed; in others, the signs become more intense and are accompanied by 
neurological manifestations (e.g., paresthesia, taste impairment, cognitive disorders and 
dizziness), lumbar pain and anuria requiring hospitalization (Danel et al., 2001; Holmdahl 
and Blohme, 1995; Michelot and Tebbett, 1990). 
Renal failure may develop several days to weeks after initial symptoms due to OR 
sequestration in the kidney. The incidence of renal failure varies from 30-70% of patients, 
and 30-65% need temporary dialysis (Danel et al., 2001). Renal involvement is the other 
peculiarity of this poisoning and is mainly characterized by lumbar and flank pains, intense 
thirst, oliguria, polyuria, proteinuria, hematuria and leukocyturia (Carter et al., 1983; Danel 
et al., 2001; Judge et al., 2010; Michelot and Tebbett, 1990; Schumacher and Hoiland, 
1983). The blood balance shows an increase in urea and creatinine levels (Judge et al., 
2010; Michelot and Tebbett, 1990). Differential diagnosis with other nephrotoxic 
compounds, such as oxalates crystals found in certain plants (e.g. genus Philodendron 
and Dieffenbachia) and ethylenoglycol found in antifreeze products, is relatively easy. In 
these poisonings, signs and symptoms are evident during the first hours after exposure 
and circumstantial evidences can help diagnosis (Nelson and Goldfrank, 2011). 
Nephrotoxicity is characterized by an early and severe interstitial fibrosis, interstitial 
edema and tubular epithelial necrosis (Carter et al., 1983; Michelot and Tebbett, 1990; 
Rapior et al., 1989; Schumacher and Hoiland, 1983). Short and colleagues (1980) have  
shown that, when initial biopsy was made until 2-3 weeks after poisonings, specimens 
exhibited pronounced focal tubular damage with tubulorrhexis, cast formation and severe 
interstitial edema with patchy infiltration of lymphocytes, plasma cells and some 
polymorphs (Short et al., 1980) . The glomeruli showed only slight mesangial cell reaction. 
In the later biopsy specimens (obtained 7-8 weeks after poisoning), the mild glomerular 
reaction was still present but the major features were tubular dilatation and cellular 
atrophy with groups of apparently normal tubules between damaged areas. In both cases 
the interstitial edema was much less in the later specimens, but there was early fibrosis 
between the damaged tubules. A mild mononuclear inflammatory cell infiltration was 
present. Immunofluorescence studies showed no significant deposition of 
immunoglobulin, complement or fibrin in glomeruli, but immunoglobulin G, immunoglobulin 
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A and fibrin were isolated from tubular casts (Short et al., 1980). Therefore, the existence 
of renal alterations as a consequence of some immune reaction cannot be excluded. 
In poisoning due to C. rubellus, most cases have not been admitted to hospital before 
8-14 days after the mushroom ingestion and then the clinical picture is that of an acute 
renal failure (Schumacher and Hoiland, 1983). It is estimated that 30-45% of individuals 
who ingest nephrotoxic Cortinarius mushrooms develop acute renal failure (Danel et al., 
2001). Of these, half usually recover the renal function and half progress to chronic renal 
insufficiency and require maintenance hemodialysis or kidney transplant (Dickman and 
Grollman, 2010). 
Some patients may become asymptomatic and the renal injury is only identified by 
biochemical tests (Nagaraja et al., 2012). 
In a study of 26 patients with nephrotoxicity secondary to Cortinarius mushroom 
ingestion, the incidence of end-stage renal failure requiring dialysis and renal 
transplantation was approximately 8 (Bouget et al., 1990), whereas 9  of 22 Swedish 
patients (41%) developed end-stage renal disease after ingesting mushrooms from 
Cortinarius species (Holmdahl and Blohme, 1995). 
Liver injury has also been observed based on increase of transaminases and bilirubin 
levels, hepatomegaly, hepatalgia, and lipoidosis and necrosis lesions evidenced by 
histological analysis (Gryzmala, 1965; Grzymala, 1965b), but most of studies ruled out 
liver involvement (Danel et al., 2001). 
Worth mentioning, OR is currently being tested as a potential treatment for metastatic 
renal cancer based on its highly selective toxicity to renal cells (Hedman et al., 2012). 
  
1.4.3.2 Mycological and toxicological analysis 
Several analytical methods were developed for the analysis of both mushrooms and 
biological samples, such as serum, renal tissue and stomach contents. The ferric-OR 
reaction could be useful for both mycologists and medical personnel by demonstrating 
whether an unknown Cortinarius specimen contains, or not, OR. Schumacher and Hoiland 
(1983) have proposed a rapid qualitative test to detect OR in mushrooms. A fresh or dried 
mushroom is crushed in 5 volumes of water and filtered after 10 minutes at room 
temperature. The filtrate is then mixed with an equal amount of 3% ferric chloride 
hexahydrate (FeCL3:6H2O) dissolved in 0.5N hydrochloric acid (HCl) (Schumacher and 
Hoiland, 1983). The presence of OR is suspected if a dark grey-blue color ink appears. 
However, other authors described an immediate change of the yellowish liquid to purple-
red or violet (Kirchmair and Poder, 2011). 
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Thin-layer chromatography can be used for separation prior to proof of the presence 
of toxins under UV light. A simplified procedure for detecting OR is as follows: a small 
piece of dried fungus is crushed and extracted in 50% ethanol, allowed to stand for 15 min 
at room temperature, and then the extract is applied to a silica gel plate and 
chromatographically developed by n-butanol:acetic acid:water (3:1:1). After drying, the 
plate is sprayed with 2% FeCl3 in 0.5 N HCI. OR is visible as a navy blue spot from the 
application point (retention factor (Rf) of 0.25-0.5), orellinine as a dark blue spot, and 
orelline as a light blue spot (Horn et al., 1997; Schumacher and Hoiland, 1983). 
Other analytical procedures are available, such as electrophoresis (Oubrahim et al., 
1997) and high-performance liquid chromatography (HPLC) with photodiode array (Koller 
et al., 2002), electrochemical (Holmdahl et al., 1987) and UV (Cantin et al., 1989) 
detection. In these last two methods, reversed-phase ion-pair HPLC with phosphate-
containing eluent20 and amide, and C18 columns with phosphoric acid as the eluent10, 
were employed. OR has also been detected in single MS mode using electron impact 
(Holmdahl et al., 1987) and electrospray ionization (Herrmann et al., 2012; Horn et al., 
1997; Koller et al., 2002). 
Brondz et al developed two methods, HPLC-MS and GC-MS, to analyze rat stomach 
content samples, after ingestion of C. orellanus (Brondz and Brondz, 2012; Brondz et al., 
2012). 
In a renal biopsy specimen, OR can be detected up to 6 months after poisoning by 
performing a thin-layer chromatography technique (Andary et al., 1989; Rapior et al., 
1989; Rohrmoser et al., 1997). Orelline, the di-reduction metabolite, has also been found 
in renal biopsies in cases of OR poisoning, and possibly originates from either the 
mushroom itself or from extra- or intrarenal metabolism of OR (Dickman and Grollman, 
2010).  
Since OR is rapidly concentrated in the kidney, it will not be detected neither in urine 
nor in blood and dialysis fluids at the time when the first symptoms appear (Frank et al., 
2009). Toxin in plasma can be only detected for up to 2 weeks after ingestion (Andary et 
al., 1989; Rapior et al., 1989). However, Andary and colleagues (1989) were able to 
detect a plasma OR concentration of 20 µmol/L in a sample obtained from a patient 9 
days after eating two mushrooms, and they used hemodialysis to effectively clear the 
circulating toxin. The toxin is not detected in urine samples collected as early as 2 days 
after ingestion and as late as 18 days (Rapior et al., 1989). 
Light microscopy has also been useful to highlight characteristic renal 
histopathological findings, such as acute renal injury and interstitial edema and invasions 
of inflammatory cells with interstitial nephritis (Frank et al., 2009). 
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1.4.4 Treatment 
There is no specific antidote to OR poisoning, treatment being mainly supportive care 
as well as the use of hemodialysis, as needed. Prolonged monitoring of renal function is 
necessary because of the slow resolution of kidney dysfunction (Barceloux, 2008). 
Emesis or gastric lavage might, in theory, be indicated if the patient is seen earlier 
than 6 hours after ingestion. Oral activated charcoal may be used if given early, although 
its efficacy has not been established (Spoerke and Rumack, 1994). 
Extracorporeal hemoperfusion, hemodialysis and plasmapheresis are techniques 
used to remove the toxin from circulation but should only be considered if the patient is 
seen within 1 week after ingestion (Busnach et al., 1983; Fulde et al., 1998; Horn et al., 
1997; Kilner et al., 1999; Montoli et al., 1999; Rapior et al., 1989). Beyond that period, the 
use of hemodialysis depends only on the need to support renal function (Barceloux, 
2008). About half of the patients requiring dialysis did not recover kidney function (Danel 
et al., 2001). Heath and colleagues reported the successful treatment of two persons by 
hemoperfusion over resin filters started up 5 days after ingestion of C. speciosissimus 
(Heath et al., 1980). In the series of C. orellanus poisonings reported by Bouget et al., of 
the 12 patients who had acute renal failure, 8 required hemodialysis (Bouget et al., 1990). 
Rapidor et al. reported a case of acute renal failure after ingestion of two C. orellanus 
mushrooms. The patient was treated on day 10 by hemodialysis and charcoal 
hemoperfusion. The OR serum level was 6.12 mg/mL before hemodialysis, and no toxin 
could be detected after treatment (Rapior et al., 1989). 
There are also reports of cases where the use of corticosteroids, N-acetylcysteine 
and selenium allowed clinical improvement (Kilner et al., 1999; Wornle et al., 2004). N-
acetylcysteine is a glutathione donor and antioxidant (Richard et al., 1995) and the 
selenium is an essential component of several major metabolic pathways including 
immune and antioxidant defense systems (Brown and Arthur, 2001). It has been shown 
that selenium improves the clinical outcome of patients with severe inflammatory 
response syndrome (Angstwurm et al., 1999). Wornle et al. demonstrated that therapy 
with selenium contribute to the subsequent improvement in renal function of patients 
intoxicated with C. specisossimus (Wornle et al., 2004).  In the series reported by Bouget 
and colleagues, a treatment with corticosteroids (prednisolone, 10mg/Kg/day for 3 days 
and 1 mg/Kg/day for 3 weeks) initiated in nine patients between the 11th and 19th day post 
ingestion, did not change the evolution of the renal failure (Bouget et al., 1990). N-
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acetylcysteine was given in one case on the 11th day without any better efficacy (Kilner et 
al., 1999). 
It has been emphasized that forced diuresis could rather accelerate and amplify the 
nephrotoxic process, since it possibly accentuates the accumulation of the toxins in the 
kidney and, therefore, it is not recommended (Danel et al., 2001; Schumacher and 
Hoiland, 1983). 
Complete recovery of renal function is attained only in 30% of the poisoned patients, 
with the majority of patients presenting a healing of fibrosis and a variable loss of renal 
function. Long-term renal replacement therapy is needed in 20-40% of patients (Bouget et 
al., 1990; Kilner et al., 1999). Therefore, renal transplantation has been considered, but 
should not be performed too early in the course of illness. The median time for transplant 
are 9-10 months after presentation, wherein appears safe without risk of further toxicity 
from OR (Danel et al., 2001; Holmdahl and Blohme, 1995). 
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2. AIMS 
 
OR is a potent toxin produced by Cortinarius mushrooms which grow throughout in 
Europe and parts of North America. Cortinarius orellanus and Cortinarius speciossimus 
are the major OR-containing mushrooms which are responsible for causing human 
intoxication. OR poisoning is characterized by severe oliguric acute renal failure, with a 
mortality rate of 10-30%. Chemically, OR resembles the bipyridyl herbicides diquat and 
PQ. The mechanism of toxicity of these compounds implicates oxidation/reduction of 
chain reactions, with ultimate formation of free radicals and lowering of NADPH 
concentration.  
Given the similarities identified between OR and PQ, we can suspect that the 
antidotal compound used in PQ poisoning, LAS, has a great potential to be successfully 
used in orellanine poisoning. 
Considering the absence of a specific antidote for OR poisoning, two types of in vivo 
studies were performed in order to prove the efficacy of LAS against OR intoxication: a 
short-term study (sacrifice time at 24 hours) and a survival study. The first study was 
conducted to histological damage, biochemical analysis in plasma and urine, oxidative 
stress biomarkers (lipid peroxidation and GSH/GSSG) and total RNA quantification. The 
subsequent survival study aimed to evaluate the long-term effectiveness of LAS. Another 
aim of this dissertation was to evaluate the toxic effects of OR in the target organs and to 
evaluate possible poisoning signs and symptoms not previously described. 
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3. MATERIALS AND METHODS 
 
3.1 Chemicals and drugs 
 
OR was purchased from Apollo Scientific (Denton, Manchester). LAS was obtained 
from. Xylazine and ketamine were purchased from Bayer (Carnaxide, Portugal) and 
Vetoquinol (Barcarena, Portugal), respectively. RNALater, TRI Reagent, RNASE free 
water, 5,5’-dithiobis-2-nitrobenzoic acid (DTNB), Nicotinamide adenine dinucleotide 
phosphate (NADPH), glutathione reductase, L-glutathione oxidized, L-glutathione 
reduced, 2-vinylpyridine, RNAlater, 2-thiobarbituric acid (TBA), malondialdehyde (MDA) 
and X-triton were purchased from Sigma-Aldrich (St. Louis, USA). Percholoric acid 
(HClO4), Potassium bicarbonate (KHCO3), Ethylenediaminetetraacetic acid (EDTA), 
Disodium phosphate (Na2HPO4), sodium hydroxide (NaOH), Monosodium phosphate 
(NaH2PO4), potassium dihydrogen phosphate (KH2PO4) and paraffin  were obtained from 
Merck (Darmstadt, Germany). Sodium chloride (NaCl) was purchased from VWR (Leuven, 
Belgium), glycoblue from Ambion (Lithuania), isopropyl alcohol ( C3H8O) from Panreac 
(Barcelona, Spain), chloroform (CHCl3) from Fisher Scientific (Loughborough, UK), 
buffered formalin from Klinipath (Netherlands), ethanol from Panreac AppliChem 
(Darmstadt, Germany), xylene from BDH – Prolabo, VWR International (Ireland) and 
silane from Nuova Aptaca (Canelli, Italy). 
N-acetyl-β-glucosaminidase (NAG) reagents were obtained from Diazyme Europe 
GmbH. The reagents Albumine, total protein (TP), cholesterol (Chol), high-density 
lipoprotein (HDL), creatinine, uric acid (UA), triglycerides (TG), alanine aminotransferase 
(ALT), glucose, amylase, low-density lipoprotein (LDL), lactate dehydrogenase (LDH), 
creatinine kinase (CK), creatinine kinase MB (CK-MB), phosphate, magnesium (Mg), 
calcium (Ca), iron, aspartate aminotransferase (AST), chloride, Pseudocholinesterase 
(PchE), lactate and γ-glutamyl-transpeptidase (GGT)  were purchased from PVL LTD 
(Lisbon, Portugal). 
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3.2 Animals and experimental design 
 
In the present work, two in vivo studies were performed to evaluate the potential 
protective effect of LAS against OR toxicity: a short-term study (24 hours) and a survival 
study (5 months). The short-term study was performed using adult male Wistar rats 
obtained from Charles River S.A. (Barcelona, Spain), with a mean weight of 150-200 g. 
Adult male CD-1 mice (Harlan, Udine, Italy), weighing 30-40 g, were used in all 
experiments of the survival rate study. In both studies, before starting the experiments, 
animals were maintained under a controlled environment (12/12 h light/darkness, 22±2°C 
room temperature, 50-60% humidity) for at least 1 week (quarantine) and 5 months, for 
both the short and the survival studies, respectively. Animals were allowed access to tap 
water and rat chow ad libitum during these periods. 
All procedures were carried out to provide an appropriate animal care, minimizing 
their suffering.  
 
 
3.2.1 Short-term study 
 
Our work started with a short-term (24 h) study to evaluate the effectiveness of LAS in 
protecting lung, liver, kidney, heart and spleen against the toxicity of OR. In order to 
create a real scenario of intoxication, since intoxicated people only arrive to emergency 
rooms hours or even days after mushrooms ingestion, LAS was only administered to 
animals 4 h after OR administration. After the quarantine period, 20 animals were 
randomly divided in four groups of 5 animals each that were treated as follows: (1) control 
group, animals subjected to two 0.9% saline solution (0 and 4 h); (2) OR group, animals 
exposed to one dose of OR (15 mg/kg) followed by one 0.9% saline solution  4 h after OR 
administration; (3) LAS group, animals exposed to a 0.9% saline solution followed by one 
dose of LAS (200 mg/kg) 4 h after saline administration; and (4) OR + LAS group, animals 
exposed to one dose of OR (15 mg/kg) followed by one dose of LAS (200 mg/kg) 4 h 
later. All drugs were given intraperitoneally (i.p.). The dose of OR used was chosen based 
on previously reported data indicating to be the lethal dose 50 (LD50) in mouse (Prast et 
al., 1988). The LAS dose was selected according to the study performed by Dinis-Oliveira 
and colleagues (Dinis-Oliveira et al., 2007). 
Each animal was individually housed in a metabolic cage where it was kept during the 
whole time of experiment (24 h). Animals were fasted during the entire experimental 
period but water was given ad libitum.  Twenty-four hours after the last administration, all 
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animals were anesthetized with xylazine/ketamine i.p. (10 and 100 mg/kg, respectively). 
Animals were placed in the decubito supine position and the thorax was opened by two 
lateral transversal incisions and one central longitudinal incision to expose the aorta 
artery. Blood, urine and solid tissue samples (liver, kidneys, lungs, heart and spleen) were 
collected for subsequent biochemical analysis.  
 
 
3.2.2 Survival rate study 
 
For the evaluation of survival rate, 6 animals were randomly divided into two groups 
of 3 animals each. The two groups were treated as follows: (1) OR group, animals 
exposed to one dose of OR (3.5 mg/kg i.p.) followed by one 0.9% saline solution i.p. 4 h 
after OR administration; (2) OR+LAS group, animals exposed to one dose of OR (3.5 
mg/kg i.p.) followed by one dose of LAS (200 mg/kg i.p.) 4 h later. The dose of OR 
administered was chosen based on previously reported data indicating to cause a 
deteriorated renal function and an increased oxidative damage in rats kidneys (Nilsson et 
al., 2008). 
Body weight, motor activity, dyspnea, piloerection, dehydration, bleeding, color of 
mucous, abdominal pain, signs and changes in behavior, if present, were noted and 
recorded. All mentioned parameters were monitored for 5 months.  
 
 
3.3 Short-term study  
3.3.1 Blood collection and biochemical analysis 
 
In the short-term study, the blood was collected with a heparinized needle from the 
inferior vena cava and was placed into a heparinized containing tube. Blood samples were 
subjected to water bath at 37°C for 2-3 min and were then centrifuged (5000g, 4°C, for 4 
min). The plasma supernatant was collected into tubes and stored at -80°C until 
determination of albumin, total protein, cholesterol, high-density lipoprotein (HDL), 
creatinine, uric acid, triglycerides (TG), alanine aminotransferease (ALT), glucose, 
amylase, low-density lipoprotein (LDL), lactate dehydrogenase (LDH), creatine kinase 
(CK), creatine kinase isoform MB (CK-MB), phosphate, magnesium, calcium, iron, 
aspartate aminotransferase (AST), chloride, pseudocholinesterase (PchE) and lactate. 
Plasma biochemical parameters were measured on an AutoAnalyzer (PRESTIGE 24i, PZ 
Cormay S.A.).  
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3.3.2 Urine collection 
 
Urine samples were centrifuged (13000g, 4°C, for 10 min) and stored (-80°C) until 
determination of urea, creatinine, total protein and uric acid. Urinary biochemical 
parameters were measured on an AutoAnalyzer (PRESTIGE 24i, PZ Cormay S.A.). NAG 
and clearance of creatinine were determined. Clearance of creatinine was calculated as 
follows:  
𝑈𝑟𝑖𝑛𝑎𝑟𝑦 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 ×𝑢𝑟𝑖𝑛𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 24 ℎ𝑜𝑢𝑟𝑠
𝑃𝑙𝑎𝑠𝑚𝑎𝑡𝑖𝑐 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 ×1440 ×𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡
 (mL/min/Kg).  
 
 
3.3.3 Assessment of NAG activity 
 
Urinary NAG activity was assayed according to the kit DZ062A-K Diazyme N-Acetyl-
β-D-glucosaminidase (NAG) assay (USA).  The assay principle was determined by the 
kinetic spectrophotometric measurement of the rate of appearance of the reaction product 
of a direct enzymatic cleavage of a synthetic substrate by NAG. NAG hydrolyzes 2-
methoxy-4-(2’nitrovinyl)-phenyl 2-acetamido- 2-deoxy-β-D-glucopyranoside (MNP-
GlcNAc) to 2-methoxy-4-(2’-nitrovinyl)-phenol. Briefly, the assay mixture consisted of 10µL 
sample, calibrator or standard and 150µL reagent mix (MNP-G1cNA (dissolved in 
hydrochloric acid) citric acid (dissolved in potassium phosphate, pH 4.7) 5:1 (v/v)). The 
samples were incubated at 37°C for 5 min in plate reader (BioTek Instruments, Vermont, 
US). The product formation was detected by development of color at 505 nm upon 
addition of 50µL reagent 3 (sodium carbonate buffer, pH 10). Urinary NAG activity was 
assayed in triplicated and results were expressed in U/L. 
 
 
3.3.4 Collection and processing organs for biochemical analysis 
 
After blood collection, lung, liver, kidney, heart and spleen were removed, weighted 
and processed as follows: (i) slices of lung, liver, kidney, heart and spleen were kept in 
RNAlater and stored at -80°C for future total RNAquantification and quantitative PCR 
analysis; (ii) segments of lung, liver, kidney, heart and spleen were placed in 4% buffered 
formalin and used for histological and immunohistochemistry analysis; (iii) segments of 
lung, liver, kidney, heart and spleen were homogenized (1:4 m/v) with an Ultra-Turrax® 
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homogenizer in cold phosphate buffer [(2.67 g Na2HPO4, 1.7025 g KH2PO4 and 0.5 mL 
Triton X-100), pH 7.4] and centrifuged (3000g, 4°C, for 10 min). Aliquots of the resulting 
supernatants were transferred to eppendorfs and centrifuged again (13000 g, 4°C, for 10 
min). The resulting supernatants were divided in aliquots and stored (-80°C) until posterior 
activity and biochemical parameters quantification (albumin, TP, chol, HDL, glucose, 
creatinine, uric acid, TG, ALT, amylase, GGT, LDL, LDH, CK, CK-MB, phosphate, Mg, Ca, 
iron, AST, chloride and lactate); (iv) perchloric acid (10%) was added to the resulting 
supernatant described above in the proportion of 1:1 and then centrifuged at 13000 g, 
4ºC, for 10 min. The resulting supernatant was stored (−80°C) until quantification of total 
glutathione (GSHt), reduced glutathione (GSH), oxidized glutathione (GSSG) and lipid 
peroxidation. 
 
 
3.3.5 Quantification of GSHt, GSH and GSSG 
 
The GSHt and GSSG contents in lung, liver, kidney, heart and spleen perchloric acid 
supernatant were determined by the DTNB-GSSG reductase recycling assay, performed 
in triplicate, as described before (Pontes et al., 2008), with some modifications. Briefly, the 
thawed acidic supernatant was neutralized with equal volume (200µl) of 0.76 M KHCO3 
and centrifuged for 10 min at 13000g (4°C). For measurement of GSHt, 100 µL/well of the 
neutralized supernatants, standards or blank were added in triplicate to 96-well microtiter 
plates, followed by 65 µL/well of freshly prepared reagent containing 0.24 mM NADPH 
and 0.7 mM DTNB in phosphate buffer and deionized water. Plates were then incubated 
at 30°C in plate reader (BioTek Instruments, Vermont, US), for 15 min prior to the addition 
of 40 µL/well of a 10IU/mL glutathione reductase solution in phosphate buffer. The 
stoichiometric formation of 5-thio-2-nitrobenzoic acid was followed for 3 min at 415 nm 
and compared to a standard curve. Standards were made in perchloric acid solution 5%, 
being the range of concentrations used between 0 and 15 nmol/mL. 
To determine GSSG levels, before the neutralization 10 μL of 2-vinylpyridine was 
added to the samples homogenates, standards and blanks and mixed continuously for 1h, 
on ice, to block the reduce glutathione (GSH). GSSG was then measured as described 
above for GSHt. The GSSG standard solutions were also made in 5% perchloric acid with 
concentrations that ranged between 0 and 8 nmol/mL. The molar GSH levels were 
calculated by subtracting the GSSG content for the total glutathione content (𝐺𝑆𝐻 =
𝐺𝑆𝐻𝑡 − 2 × 𝐺𝑆𝑆𝐺). Results are expressed in nmol of GSH or GSSG per mg of protein. 
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3.3.6 Evaluation of lipid peroxidation 
 
Lung, liver, kidney, heart and spleen lipid peroxidation were measured by the 
thiobarbituric acid reactive substances (TBARS) assay methodology.  TBARS assay 
involves the reaction of malondialdehyde (MDA) with thiobarbituric acid (TBA) under 
strong acidic condition and heating, leading to the formation of pink colored products 
which can be measured by fluorometric methods (Niki, 2014). It was used the improved 
assay method described by (Buege and Aust, 1978), with slight alterations. Briefly, the 
assay mixture consisted of 200µL sample, blank or standard and 200µL TBA (dissolved in 
distilled water). The samples were vortex mixed and incubated at 80°C for 60 min in water 
bath. After incubation, mixture was cooled in water vortex mixed. Fluorescence were read 
(BioTek Instruments, Vermont, US ) at  ʎex/em = 530-590 nm. The MDA standard solutions 
were also made in 5% perchloric acid with concentrations that ranged between 0 and 30 
µmol/mL. The results were expressed as nmol of malondialdehyde (MDA) equivalents/mg 
protein.  
 
 
3.3.7 RNA extraction and real-time PCR 
 
Total RNA isolation was performed by adding 800µL of TRI Reagent to lung, liver, 
kidney, heart and spleen samples. All specimens were homogenized by mechanical 
disruption using the Ultra-Turrax® instrument and total RNA was extracted in RNAse-free 
environment. The homogenized samples were incubated for 5 min at room temperature. 
160µL chloroform was added per 800µL of TRI Reagent. The samples were mixed 
vigorously and then centrifuged at 12,000 x g for 10 min at 2-8 °C. Centrifugation 
separated the biphasic mixtures into the lower red, phenol-chloroform phase and the 
upper colorless, aqueous phase. The RNA was precipitated from aqueous phase by 
mixing with 800µL of isopropanol. The samples were incubated at room temperature for 
10 min and centrifuged at 12,000 x g for 10 min at 2-8 °C. The supernatant was removed 
and the RNA pellet was washed once with 75% ethanol. The pellet was air dried and 
dissolved in water RNAse free. The RNA concentration was determined by OD260 
measurement using a NanoDropH ND-1000 Spectrophotometer (NanoDrop Technologies, 
USA), and the purity of the total RNA extracted was assessed by measuring the 
absorbance at 230 and 280 nm. 200 ng of total RNA was reverse-transcribed using the 
iScript Select cDNA Synthesis it (Bio-Rad, Hercules, California, USA) according to the 
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manufacturer’s protocol. All cDNA samples were stored at -20 °C until quantitative real-
time PCR (qPCR) analysis. qPCR was performed in iQ™ 5 Real-Time PCR detection 
System (Bio-Rad, Hercules, California, USA) in 96-well plates with a reaction volume of 
20 µL and runs up to 40 cycles using iQ™ SYBER® Green Supermix. The final PCR 
reaction mixture of 10 µL contained 0.25 µL of cDNA samples, 5 µL of iQ™ SYBER® 
Green Supermix, 0.25 µL of each primer and 4.25 µL of RNase-free water. The cycling 
conditions were set as follows: Taq DNA polymerase activation at 95 °C for 3 min, 
amplification steps: desnaturation at 95 °C for 15 s, annealing at 60 °C for 15 s, and 
extension at 72 °C for 15 s with fluorescence acquisition. Two highly stable reference 
genes for RNA polymerase II (RNAPII) were chosen (βeta-actin, GAPDH) as well as two 
ribosomal 18S and 28S genes transcribed by RNA polymerase I (RNAP I). All cDNA 
samples were measured in duplicate, and the relative transcript levels were quantified by 
the threshold cycle (Ct) value. All primers were designed using the Beacon Designer 
Software (version 7.2, PREMIER Biosoft Internation, Palo Alto, CA, USA). 
 
 
3.3.8 Histological analysis 
 
Histology sampling protocol was designed with the goal of ensuring the validity of the 
estimators to minimizing the variance contribution from sampling variation. The spleen 
was cut in the midsagittal plane in two halves. The heart, kidneys and lungs were divided 
in two equal parts: the cranial and caudal parts. Each organ half was then randomly 
selected for histological analysis. Liver was cut into ≈ 4 mm thick slabs and then a 
systematic selection was carried out and sampled pieces were processed for light 
microscopy. Organs fragments were fixed in 4% buffered formalin and processed for 
histological examination by light microscopy. After fixation (24 hours), the tissues were 
dehydrated through a series of graded ethanol solutions (70-99.8%), cleared in xylene, 
and impregnated and embedded in paraffin. Each organ was sectioned (Microtome - 
Leica RM 2255, Germany) into thin sections (5 µm thick). For improving section adhesion, 
the sampled sections were mounted in silane coated microscope slides. The sections 
were then stained with haematoxylin-eosin (H&E) before being coversliped. 
 
 
3.4 Statistical analysis 
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All data obtained were expressed as mean ± SEM (standard error of the mean). All 
statistical analysis was performed using GraphPad Prism® (version 6.01, GraphPad 
Software, San Diego, California, USA). The Shapiro-Wilk test was performed to check 
normality of the data. Statistical comparisons were done using the one-way ANOVA (in 
case of normal distribution) followed by the Bonferroni post hoc test or Kruskal-Wallis (in 
case of not normal distribution) followed by the Dunn’s post hoc test. P values lower than 
0.05 were considered statistically significant. 
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4. RESULTS 
 
4.1 Short-term study 
 
4.1.1 Organs weight  
 
As an indirect measure of organ damage, each organ (kidney, liver, lung, spleen and 
heart) had their weight registered and the weight ratio of each organ was taken to body 
weight. No significant differences were observed between OR group and the control group 
concerning the kidney weight /body weight ratio, liver weight /body weight ratio, lung 
weight /body weight ratio, spleen weight /body weight ratio and heart weight /body weight 
ratio (Table 4).  
 
Table 4 – Kidney weight/body weight ratio, liver weight /body weight ratio, lung weight 
/body weight ratio, spleen weight /body weight ratio and heart weight /body weight ratio of 
control, OR, LAS and OR+LAS groups. 
 Control OR LAS OR + LAS 
Kidney 7.15±0.30 7.37±0.15 7.24±0.27 7.10±0.21 
Liver 28.52±1.07 28.99±0.67 28.24±0.68 28.43±0.56 
Lung 4.78±0.17 4.78±0.19 4.69±0.18 4.54±0.14 
Spleen 
Heart 
2.20±0.19 
3.29±0.14 
2.28±0.14 
3.38±0.10 
2.48±0.20 
3.04±0.03 
2.15±0.048 
3.08±0.19 
Values are given as mean±SEM (n = 5). 
 
 
4.1.2 Biochemical analysis in plasma and urine 
 
Plasma biochemistry quantified 24h after intoxication only showed slight variations 
(Table 5). HDL and uric acid levels were significantly increased in the OR group 
(16.44±1.85, p<0.05, and 1.14±0.39 mg/dL, p<0.05, for HDL and uric acid, respectively) 
as compared with control group (9.48±0.60 and 0.20±0.07 mg/dL for HDL and uric acid, 
respectively). While this effect was reverted in the OR+LAS group (14.56± and 0.30±0.12 
mg/dL for HDL and uric acid, respectively) (Figure 6A and 6B). On the other hand, 
amylase, CK and PChE levels were significantly increased in the OR+LAS group 
(399.00±16.39, p<0.05, 2060.00±282.90, p<0.05, and 492.90±58.96, p<0.05, U/L for 
amylase, CK, PChe respectively) compared to control group (325.10±16.84, 
656.00±147.80 and 227.40±48.57) (Figure 6C, 6D and 6E). The calcium levels were 
significantly decreased in the OR (7.97±0.12, p<0.05) and OR+LAS (7.05±0.28, p<0.01) 
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group between control group (9.21±0.47) (Figure 6F). There was a statistically significant 
increase in lactate and total protein in OR-treated animals (35.20±5.38, p<0.05, and 
53.59±1.51, p<0.05) compared to OR+LAS group (17.60±1.03 and 48.19±1.86) (Figure 
6G and 6H). The chloride levels significantly decreased in OR group (93.84±0.31, p<0.05) 
compared with OR+LAS-treated animals (99.12±0.31) (Figure 6I). 
 
Table 5 – Plasma biochemistry following 24h of intoxication. 
Evaluated 
parameter 
Control OR LAS OR + LAS 
Albumin (g/L) 3.09 ±0.17 3.42±0.01 3.07±0.07 3.37±0.215 
TP (g/L) 48.19±1.86 53.59±1.51ᶿ 47.44±1.29 41.81±4.52 
Chol(mg/dL) 32.18±2.15 54.86±5.80 47.90±5.59 48.38±11.79 
HDL (mg/dL) 
LDL (mg/dL) 
9.48±0.60
*
 
14.03±2.97 
16.44±1.85
*
 
15.16±1.02 
2.08±1.08 
18.66±4.86 
14.56±1.40 
12.68±0.88 
Glucose (mg/dL) 85.96±11.20 98.60±10.68 98.60±5.20 110.80±8.97 
Creatinine (mg/dL) 0.04±0.02 0.003±0.003 0±0 0±0 
UA (mg/dL) 0.20±0.07 1.14±0.39
*
 0.52±0.08 0.30±0.16 
TG (mg/dL) 3.28±2.02 4.18±2.73 13.38±5.12 12.62±6.22 
Amylase (U/L) 325.10±16.84 367.70±23.06 319.10±18.73 399.00±16.39
#
 
ALT (U/L) 0.38±0.23 0.08±0.08 0.08±0.06 0.40±0.25 
LDH (U/L) 455.20±103.80 557.70±86.49 644.90±90.29 759.40±129.20 
AST (U/L) 115.70±12.42 168.80±24.05 124.40±6.95 149.50±13.26 
CK (U/L) 656.00±147.80 1657.00±418.20 1718.0±419.30 2060.00±282.90
#
 
CK-MB (U/L) 127.00±26.63 126.2±22.49 153.60±24.71 204.30±31.94 
Chloride (mg/dL) 95.88±2.67 93.84±0.31ᶿ 95.95±2.98 99.12±0.31 
Phos (mg/dL) 9.72±0.44 9.03±0.55 9.15±0.811 9.28±0.64 
Mg (mg/dL) 3.15±0.30 3.18±0.35 3.08±0.34 3.21±0.36 
Ca (mg/dL) 9.21±0.47 7.97±0.12
*
 9.35±0.11 7.05±0.28
##
 
Iron (mg/dL) 289.70±44.86 210.70±82.99 371.10±109.20 630.00±328.30 
PChe (U/L) 227.40±48.57 273.40±27.79 356.90±24.25 492.90±58.96
#
 
Lactate (mg/dL) 27.50±1.32 35.20±5.38ᶿ 25.80±3.46 17.60±1.03 
Values are given as mean±SEM (n = 5); * p < 0.05 OR vs. Control; # p < 0.05 OR+LAS vs. Control; ᶿ p < 0.05 
OR vs OR+LAS; ## p < 0.01 OR+LAS vs. Control. 
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Figure 6. Plasmatic levels of (A) HDL, (B) uric acid,  (C) amylase, (D) CK,  (E) PChE, (F) 
Calcium , (G) lactate , (H) total protein and (I) chloride in control, OR, LAS and OR+LAS 
groups. Results are presented as mean ± SEM, and were obtained from 5 animals from 
each treatment. Statistical comparison were using Kruskal-Wallis ANOVA on Ranks 
followed by the Dunn’s post hoc test (* p < 0.05 OR vs. Control; # p < 0.05 OR+LAS vs. 
Control; ᶿ p < 0.05 OR vs OR+LAS; ## p < 0.01 OR+LAS vs. Control). 
 
As shown in Figure 7A, animals from group OR+LAS exhibited an increase of NAG 
levels in urine compared to control group (15.57±3.88 vs 7.38±1.33 U/L from NAG). 
However, this parameter was kept near to control levels in the OR group (7.76±1.54 U/L 
from NAG). Analogous results were obtained for TP (3.66±0.32, p<0.01, vs 1.04± 0.26g/L 
for total protein), while for the clearance of creatinine it was observed, in OR group, an 
increase compared to control and OR+LAS groups (47.53±33.19 vs 6.18±5.99 vs 0) 
(Figure 7B and 7C). The animals exposed to OR+LAS had lower levels of urea compared 
to the control group (115.60±27.60, p<0.05, vs 220.60±19.97 mg/dL for urea) (Figure 7D). 
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Figure 7. Urine levels of (A) NAG, (B) total protein,  (C) clearance of creatinine and (D) 
urea  in control, OR, LAS and OR+LAS groups. Results are presented as mean ± SEM, 
and were obtained from 5 animals from each treatment. Statistical comparision were using 
Kruskal-Wallis ANOVA on Ranks followed by the Dunn’s post hoc test (# p < 0.05 
OR+LAS vs. Control; ## p < 0.01 OR+LAS vs. Control). 
 
 
 
 
Table 6 – Urinary biochemistry.  
Evaluated 
parameter 
Control OR LAS OR + LAS 
Albumin (g/L) 0 ± 0 0±0 0±0 0±0 
TP (g/L) 1.00±0.26 1.95±0.60 2.38±0.34 3.66±0.32
##
 
Creatinine(mg/dL) 22.98±6.52 46.05±11.91 31.73±4.72 61.04±20.15 
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UA (mg/dL) 
Urea (mg/dL) 
NAG (U/L) 
Clearance 
Creatinine 
(mL/min/Kg) 
9.84±1.15 
220.60±19.97 
7.38±1.33 
6.18±5.99 
8.54±3.61 
205.90±28 
7.76±1.54 
47.43±33.19 
8.66±3.79 
185.80±26.33 
8.91±1.64 
0±0 
14.98±1.10 
115.60±27.60
#
 
15.57±3.88 
0±0 
 
Values are given as mean±SEM (n = 5); # p < 0.05 OR+LAS vs. Control; ## p < 0.01 OR+LAS vs. Control. 
 
 
 
4.1.3 Biochemical analysis in organs 
 
The mechanism of toxicity involved in the poisoning by orellanine is not yet fully 
understood. Therefore, we evaluated the clinical biochemistry of the kidney, liver, lung, 
spleen and heart (Attachements A1, A2, A3, A4 and A5). 
 
A significant increase was observed in the lung HDL levels of the OR+LAS group 
(3.12±0.77, p<0.05) as compared to the control group (0.80±0.34) (Figure 8). 
 
Figure 8. Lung levels of HDL in control, OR, LAS and OR+LAS groups. Results are 
presented as mean ± SEM, and were obtained from 5 animals from each treatment. 
Statistical comparision were using Kruskal-Wallis ANOVA on Ranks followed by the 
Dunn’s post hoc test (# p < 0.05 OR+LAS vs. Control). 
 
As shown in Fig 9, heart albumin and phosphate levels were significantly decreased in 
the OR+LAS group (0.05±0.14 g/dL and 27.58±1.49 mg/dL, p<0.05) compared to control 
and OR groups, respectively (0.10±0.03 g/dL and 32.93±0.67 mg/dL). 
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Figure 9. Heart levels of (A) albumin and (B) phosphate in control, OR, LAS and OR+LAS 
groups. Results are presented as mean ± SEM, and were obtained from 5 animals from 
each treatment. Statistical comparison were using Kruskal-Wallis ANOVA on Ranks 
followed by the Dunn’s post hoc test (# p < 0.05 OR+LAS vs. Control; ᶿ p < 0.05 OR vs 
OR+LAS). 
 
 
 
4.1.4 Oxidative stress biomarkers 
 
Due to the fact OR produces ROS during the redox cycling, oxidative stress and 
inflammatory biomarkers were also evaluated. 
As shown in Figure 10, kidney GSH levels decreased in OR+LAS group (0.94±0.38 
nmol/mg protein) when compared to control group (1.16±0.22 nmol/mg protein), although 
no statistical significance was reached. A significant increase was observed in the GSSG 
levels of the OR+LAS group (0.76±0.24 nmol/mg protein, p<0.01). In accordance, the 
GSH/GSSG ratio suffered a significant reduction in the OR+LAS group compared to the 
control group (0.58±0.23 vs 13.00±2.59, p<0.05). 
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Figure 10. Kidney levels of (A) GSH,  (B) GSSG and (C) GSH/ GSSG ratio in control, 
OR, LAS and OR+LAS groups. Results are presented as mean ± SEM, and were 
obtained from 5 animals from each treatment. Statistical comparision was performed 
using Kruskal-Wallis ANOVA on Ranks followed by the Dunn’s post hoc test (# p < 
0.05 OR+LAS vs. Control; ## p < 0.01 OR+LAS vs. Control). 
 
No significant changes in the liver GSH levels were observed between control, OR 
and OR+LAS group (Figure 11). It was observed only a tendency to decrease in both 
OR (13.13±2.33 nmol/mg protein) and OR+LAS (15.53±3.43 nmol/mg protein) groups 
when compared to control group (19.52±2.31 nmol/mg protein). A significant increase 
was observed in the GSSG levels of the OR+LAS group (14.93±1.60 nmol/mg protein, 
p<0.0001) compared to control (1.476±0.3351 nmol/mg protein) and OR (5.07±1.22 
nmol/mg protein, p<0.05) groups. In conformity, the GSH/GSSG ratio suffered a 
significant reduction in the OR+LAS group (1.14± 0.31, p<0.01) compared to the 
control group (11.28±1.89).  
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Figure 11. Liver levels of (A) GSH,  (B) GSSG and (C) GSH/ GSSG ratio in control, 
OR, LAS and OR+LAS groups. Results are presented as mean ± SEM, and were 
obtained from 5 animals from each treatment. Statistical comparision were using Kruskal-
Wallis ANOVA on Ranks followed by the Dunn’s post hoc test (## p < 0.01 OR+LAS vs. 
Control; ᶿᶿᶿ  p < 0.001 OR vs OR+LAS; #### p < 0.0001 OR+LAS vs. Control). 
 
 
There were no significant changes in lung GSH levels, but it was observed a 
significant increase in the GSSG levels of the OR group when compared to control group 
(5.73±0.90 vs 1.17±0.40 nmol/mg protein, p<0.05). In accordance, the GSH/GSSG ratio 
suffered a significant reduction in the OR group compared to control group (1.80±0.39 vs 
6.67±1.05, p<0.05) (Figure 12). 
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Figure 12. Lung levels of (A) GSH,  (B) GSSG and (C) GSH/ GSSG ratio in control, 
OR, LAS and OR+LAS groups. Results are presented as mean ± SEM, and were 
obtained from 5 animals from each treatment. Statistical comparision were using 
Krusal-Wallis ANOVA on Ranks followed by the Dunn’s post hoc test (* p < 0.05 OR 
vs. Control). 
 
The amounts of GSH in its reduced state and GSSG were measured in the spleen 
but no significant differences were observed. Observing the results, the GSH/GSSG 
ratio suffered a significant reduction in both OR and OR+LAS (1.95±0.63 (p<0.01) and 
3.14±0.62 (p<0.05), respectively) groups compared to control group (6.27±1.11) 
(Figure 13). 
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Figure 13. Spleen levels of (A) GSH,  (B) GSSG and (C) GSH/ GSSG ratio in control, OR, 
LAS and OR+LAS groups. Results are presented as mean ± SEM, and were obtained 
from 5 animals from each treatment. Statistical comparison were using Kruskal-Wallis 
ANOVA on Ranks followed by the Dunn’s post hoc test (#p < 0.05 OR+LAS vs. 
Control;**p < 0.01 OR vs. Control). 
 
In Figure 14, the levels of GSH, GSSH and GSH/GSSG ratio in the heart of the 
animals can be observed. There were no significant differences of all these parameters 
between the different groups. 
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Figure 14. Heart levels of (A) GSH,  (B) GSSG and (C) GSH/ GSSG ratio in control, 
OR, LAS and OR+LAS groups. Results are presented as mean ± SEM, and were 
obtained from 5 animals from each treatment. Statistical comparison were using 
Kruskal-Wallis ANOVA on Ranks followed by the Dunn’s post hoc test  
 
Lipid peroxidation was assessed by means of MDA equivalents. The levels of MDA 
equivalents in the kidney, liver, lung, spleen and heart were also determined. As 
present in table 7, there were no significant alterations in the MDA equivalents levels 
in all considered groups.  
 
Table 7 – Amount of malondialdehyde (MDA nmol/mf of protein) in the control, 
OR, LAS and OR+LAS groups.  
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 Control OR LAS OR + LAS 
Kidney 2676.0±751.90 1187.00±234.60 2723.00±647.70 1989.00±717.20 
Liver 408.70±60.74 407.60±68.70 391.60±70.66 327.70±81.83 
Lung 1077.0±405.60 1088.00±309.50 1067.00±123.1 1757.00±649.60 
Spleen 
Heart 
2762±852.60 
1322.0±429.80 
2316±837.3 
1385.0±468.00 
1688±515.6 
2174.0±488.80 
3023±770.3 
1620.0±4462.00 
Values are given as mean±SEM (n = 5). 
 
 
4.1.5 Histology 
4.1.5.1 Kidney 
The examination of the hemisected kidney section of rats of control group revealed the 
normal morphologic features of the species (Figure 15). The cortex consists of renal 
corpuscles along with the convoluted tubules and straight tubules of the nephron, the 
collecting tubules, collecting ducts, and an extensive vascular supply. 
Morphologic alterations were observed in all groups being more numerous and more 
diverse in the kidney of rats exposed to OR+LAS (Figure 16C and F), followed by OR 
(Figure 16B and E) and LAS (Figure 16 A and D) groups. The tubules were first and 
foremost damaged by OR, probably as a result of a hypovolemic shock. It was observed 
both tubular ectasia and tubular proteinosis, and epithelial cells of the affected tubules 
exhibited marked cytoplasmic degenerative changes or necrosis and apoptosis. As 
previously mentioned, the volume of the affected tubules was apparently higher in the rats 
of OR+LAS group. 
 
 
Figure 15. Representative kidney image from rat of Control group. Renal corpuscles 
consist of the glomerulus, surrounded by a double-layered epithelial cup, the renal or 
Bowman’s capsule. The glomerular capillaries are supplied by an afferent arteriole and 
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are drained by an efferent arteriole that then branches, forming a new capillary network to 
supply the kidney tubules. The site where the afferent and efferent arterioles penetrate 
and exit from the parietal layer of Bowman’s capsule is called the vascular pole (marked 
with the circle in A). Opposite this site is the urinary pole of the renal corpuscle, where the 
proximal convoluted tubule begins (thicker arrow in A). Lying directly adjacent to the 
afferent and efferent arterioles and adjacent to some extraglomerular mesangial cells at 
the vascular pole of the renal corpuscle is the terminal portion of the distal straight tubule 
of the nephron. At this site, the wall of the tubule contains cells that are referred to 
collectively as the macula densa (rectangles in B). DT – Distal tubules; PT – Proximal 
tubules. 
 
Figure 16. Representative liver images from rat treated with LAS (A and D), with OR (B 
and E) and with OR+LAS (C and F). In kidney cortex proximal tubules (thin arrows in A, B 
and C) presented structural changes include those of reversible injury such as cellular 
swelling, loss of brush border, blebbing, and cell detachment and those associated with 
lethal injury necrosis and apoptosis (cell surrounded by the circle in C). In kidney medulla 
collecting ducts contain hyaline casts (dashed arrow). In entire organ area it is possible to 
observe sinusoidal dilatation (thick arrows). 
 
4.1.5.2 Liver 
The rat liver of the control group exhibited the morphological features described for 
this species with no relevant histological alteration (Figure 17). Necrotic areas with 
clustered of affected hepatocytes and inflammatory infiltrate were identified in rat livers of 
all experimental groups, LAS, OR and OR+LAS sorted this way in ascending order of 
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apparent volume of the lesions. Liver biopsy showed mild lymphocytic portal inflammation, 
the bile ducts were intact and there was no ductular reaction. Foci of lobular inflammation 
were present (Figure 18A, herein illustrated for LAS group). Small foci of lobular 
inflammation were also present in all experimental groups (Figure 18B, herein illustrated 
for OR group).  
Confluent perivenular submassive necrosis of liver calls was present, with extension to 
the midzones and periportal zones, and with associated haemorrhage within the liver cell 
plates (Figure 18C and D, herein illustrated for LAS and OR groups, respectively).  
The necrotic cells showed increased cytoplasm eosinophilia and a small, basophilic 
nucleus. Rats exposed to OR+LAS had livers with an apparent higher volume of lesions 
and with two specific ones. It was found a severe sinusoidal dilatation and haemorrhage 
(Figure 18E) and near vessel walls hepatocytes with hydropic degeneration were 
observed (Figure 18F). 
 
Figure 17. Representative images from rat of the control group. (A) In this 
photomicrograph the terminal hepatic venule (central vein, CV) is visible in the centre of 
the lobule. The hepatocytes are acidophilic and form plates and are in close contact with 
the sinusoids. (B) In these image marked with the circle is a portal triad. 
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Figure 18. (A) Representative liver image from rat treated with LAS. The portal tract 
exhibits a moderate lymphocytic infiltrate. (B) Representative liver image from rat treated 
with OR showing mild lobular inflammatory activity. (C) Representative liver image from 
rat treated with LAS with hemorrhagic necrosis (arrow) (D) Representative liver image 
from rat treated with OR where parenchymal damage, hemorrhage, and absence of viable 
hepatocytes were evident. (E) Representative liver image from rat treated with OR+LAS 
with sinusoidal dilatation (arrows). (F) Representative liver image from rat treated with 
OR+LAS where is possible to observe a hydropic change of hepatocytes (*) near to the 
wall of the vessel. 
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4.1.5.3 Lung 
In the lungs of the rats of control group alveoli, the terminal air spaces of the 
respiratory system and the sites of gas exchange between the air and the blood, were 
perfectly normal (Figure 19A). In animals treated with LAS (Figure 19B) and with OR 
(Figure 19C), the alveolar capillaries were distended. Animals treated with OR+LAS 
(Figure 19D) exhibited an enlargement of alveoli accompanied by destruction of their walls 
without obvious fibrosis. 
 
Figure 19. Representative lung images from control- (A), LAS- (B), OR- (C) and OR+LAS-
treated rats (D). Dilatation of alveolar capillaries can be observed in lungs of animals 
treated with LAS (B) and with OR (C). Enlargement of alveoli accompanied by destruction 
of their walls without obvious fibrosis was observed in animals treated with OR+LAS (D). 
 
4.1.5.4 Spleen 
Compared with the spleen of the control animals, that presented the microanatomy 
described for the species (Figure 20), the spleen from an OR-treated mouse revealed an 
overall reduction in red and white pulp cellularity (Figure 21). Microscopically, the major 
feature of the spleen of the animals treated with OR and with OR+LAS was an acute 
congestion of the red pulp, which may invade on and virtually efface the lymphoid follicles. 
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The acute congestion is in line with a clear increase of red cells volume. Neutrophils, 
plasma cells, and occasionally eosinophils were also present throughout the white and red 
pulp.  
 
 
 
Figure 20. Representative images from rat spleen of the control group. The substance of 
the spleen is divided into white pulp (WP) and red pulp (RP). White pulp consists of a 
cylindrical mass of lymphocytes arranged around a central artery (CA) that constitutes the 
periarterial lymphatic sheath. The red pulp consists of splenic sinuses surrounded by 
splenic cords (cords of Billroth). In rat, the splenic red pulp is a major site of myeloid, 
erythroid hyperplasia and megakaryocytic hyperplasia (Meg - megakaryocyte). 
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Figure 21. Representative spleen images from rat treated with LAS (A), OR (B) and 
OR+LAS (C). In all images it is possible to observe an overall reduction in red and white 
pulp cellularity and also a congestion of the red pulp due to a clear increase of red cells 
volume especially in animals treated with OR+LAS. 
 
4.1.5.5 Heart 
The cardiac muscle of the rats of both control and LAS groups revealed the 
histological features described for this species. In longitudinal sections the cells and the 
fibres they form exhibit cross-striations that were evident. In addition, it was also possible 
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to observe the intercalated discs in the cardiac muscle fibres (data not shown). In the rats 
treated with OR and with OR+LAS, circumscribed areas of ischemic necrosis - coagulative 
necrosis of myocardial fibres were well delineated. These muscle cells presented intense 
eosinophilic cytoplasm, features typical of a very recent myocardial infarct (Figure 22). 
 
Figure 22. Representative heart images from rat treated with OR (A) and OR+LAS (B). In 
both images is possible to observe a mosaic of cells composed by normal and necrotic 
myocardial fibers, the latter with intense eosinophilic cytoplasm. 
 
4.1.6 Measurement of total RNA   
 OR inhibits DNA-depended activity of RNAP II with a consequent decrease on 
messenger RNA (mRNA). We quantified the total RNA content in the kidney, liver, lung, 
spleen and heart of animals in all experimental groups. These total RNA levels were 
further normalized to organ weight. However, no differences were found for total RNA in 
the kidney, lung, spleen and heart of OR-intoxicated animals (Table 8). It was observed 
only a tendency to decreased total RNA liver levels in the OR group (1.35±0.44 µg total 
RNA/mg) when compared to control group (2.87±0.53 µg total RNA/mg) (Figure 24). 
Table 8 – Total RNA kidney, liver, lung, spleen and heart levels of control, OR, LAS 
and OR+LAS groups.  
 Control OR LAS OR + LAS 
Kidney 1.00±0.21 1.20±0.15 1.15±0.40 0.73±0.32 
Liver 2.87±0.53 1.35±0.44 1.88±0.48 2.07±0.66 
Lung 0.97±0.26 0.89±0.23 0.58±0.08 0.88±0.20 
Spleen 
Heart 
1.34±0.65 
0.89±0.10 
0.78±0.10 
1.22±0.25 
2.06±0.77 
0.79±0.22 
2.13±0.52 
0.63±0.13 
Values are given as mean±SEM (n = 5) 
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Figure 23. (A) Total RNA liver levels in control, OR, LAS and OR+LAS groups. Results 
are presented as mean ± SEM, and were obtained from 5 animals from each treatment. 
Statistical comparision were using Kruskal-Wallis ANOVA on Ranks followed by the 
Dunn’s post hoc test. 
 
4.1.7 Alterations of the transcription process 
The evaluation of the genetic transcription by RNAP II was based on GAPDH and β-
actin mRNA quantitative analysis. The relative transcript levels were quantified by the Ct 
value, which increases with a decreasing amount of template.  
The transcript levels of GAPDH mRNA in the liver samples of OR-treated showed a 
decreased (20.66±0.38, p<0,05) when compared with control group (18.06±0.66). This 
effect was reverted in the OR+LAS group (17.88±0.37, p<0,01) (Figure 24 A). Data from 
OR-intoxicated liver indicated that the transcription of β-actin mRNA showed a tendency 
to decrease (25.01±0.77), but no statistically significance (Figure 24 B) (Table 9). No 
significant differences were observed between OR group and the control group 
concerning the transcript levels of GAPDH and β-actin mRNA in the kidney, lung, spleen 
and heart (Table 9). 
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Figure 24. Relative mRNA levels of GADPH and β-actin genes in liver samples. 
Statistical comparision were using Kruskal-Wallis ANOVA on Ranks followed by the 
Dunn’s post hoc test (*p < 0.05 OR vs. Control; ᶿᶿ p < 0.01 OR vs OR+LAS). 
Also be added, RNAP I was not affected by OR poisoning since the transcription of 
ribosomal proteins S18 and S28 by RNAP I was always similar, regardless of the organ or 
experimental groups analyzed (Table 9). 
 
Table 9 – Relative mRNA levels of GADPH, β-actin, S18 and S28 genes in kidney, liver, 
lung, spleen and heart samples. 
 RNAP II RNAP I 
 GADPH β-actin S18 S28 
Kidney:  
Control 19.29±0.71 22.77±1.60 18.45±0.84 23.12±0.96 
OR 17.78±0.70 22.62±0.78 17.70±0.57 21.69±0.58 
LAS 19.16±0.90 23.18±1.36 18.55±0.76 23.15±1.08 
OR + LAS 20.67±1.45 23.28±0.78 20.07±1.60 22.59±0.57 
     
Liver:  
Control 18.06±0.66 23.09±0.59 18.84±0.80 22.46±0.70 
OR 20.66±0.38* 25.01±0.77 18.75±0.59 22.67±0.34 
LAS 18.48±0.47 23.42±0.54 18.21±0.65 22.93±0.61 
OR + LAS 17.88±0.37ᶿᶿ 23.36±0.42 17.92±0.33 21.91±0.36 
     
Lung:  
Control 20.63±1.20 19.41±1.58 21.81±1.75 21.53±0.44 
OR 18.69±1.20 22.89±1.26 18.68±1.72 21.96±0.73 
LAS 19.57±0.96 23.12±1.041 18.91±1.54 22.38±0.56 
OR + LAS 19.50±1.32 19.91±1.28 20.12±1.25 22.76±0.76 
     
 
Spleen: 
 
Control 18.46±1.25 21.36±1.68 18.50±0.65 21.30±1.12 
OR 18.32±1.33 21.89±1.47 17.69±1.43 21.65±1.48 
LAS 18.74±0.67 20.30±1.33 17.21±1.20 20.32±0.73 
OR + LAS 19.00±1.22 19.47±0.86 17.65±0.60 20.80±0.78 
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Heart:  
Control 20.29±1.08 24.57±1.32 20.90±1.08 21.18±0.96 
OR 19.02±0.50 22.98±0.55 19.31±0.89 22.81±0.21 
LAS 18.58±0.75 24.00±0.62 18.24±0.68 22.73±0.62 
OR + LAS 19.50±0.51 24.80±0.90 19.50±0.34 23.56±0.76 
Values are given as mean±SEM (n = 5); * p < 0.05 OR vs Control; ᶿᶿ  p < 0.01 OR vs OR+LAS. 
 
 
4.2 Survival rate study 
A long-term survival study for 5 months was done. All mice exposed to 3.5 mg/kg of 
orellanine did not die. The administration of OR+LAS resulted in 100% of survival. 
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5. DISCUSSION 
 
In this dissertation two types of in vivo studies were performed, in order to prove the 
effectiveness of LAS against OR intoxication: it was executed a short-term study (sacrifice 
time at 24 hours) and a survival study (5 months). 
Since kidney injury is the main concern in OR poisoning, kidney damage biomarkers 
were assessed, namely serum creatinine, total protein, uric acid and urea. Laboratory 
abnormalities by OR poisoning include leucocyturia, hematuria and proteinuria along with 
elevation of the serum creatinine and serum potassium. Depending on the severity of the 
renal failure, hyperphosphatemia, hypocalcemia and metabolic acidosis may also occur 
(Barceloux, 2008). The increasing in urea and creatinine levels in blood were also 
reported on these poisonings (Michelot and Tebbett, 1990). In other study, the levels of 
urea nitrogen (BUN), ALT and alkaline phosphatase (ALP) on blood were increased in a 
mouse 96 hours post exposed with OR (Anantharam et al., 2016). (Prast and Pfaller, 
1988) have reported progressive elevation on the serum concentrations of BUN and 
creatinine (Prast and Pfaller, 1988). Hypocalcemia was also observed in other in vivo 
study and reduced sodium ion concentration and elevated phosphorus concentration in 
serum was reported (Anantharam et al., 2016). Bedry et al. observed a massive 
rhabdomyolysis and increased CK level (Bedry et al., 1998). Our results demonstrate that 
there was a statistically significant increase in serum HDL, uric acid and hypocalcemia. 
The increased UA in OR group can either be related to a possible kidney damage or to an 
increased catabolism of purines (Prakash, 2014). Serum levels of HDL in OR group do not 
produce untoward clinical manifestations and are associated with below-average risk of 
atherosclerosis (SarDesai, 2011). The kidney of rat administered with OR evidenced 
notorious damage, with tubular ectasia, tubular proteinosis, and epithelial cells of the 
affected tubules exhibited marked cytoplasmic degenerative changes or necrosis and 
apoptosis. These histological phenotypes are in agreement with previous reports of OR 
studies in mice (Anantharam et al., 2016), rats (Prast and Pfaller, 1988; Richard et al., 
1988)  and other animals (Grzymala, 1957; 1962; 1965b). Moreover, histopathological 
kidney damage in laboratory animals is similar to those found in humans after OR 
intoxication (Horn et al., 1997; Marichal et al., 1977; Rapior et al., 1989; Short et al., 
1980). These histological kidney findings also show that LAS did not reverte the damage 
caused by OR, being that, the volume of the affected tubules was apparently higher in the 
rats of OR+LAS group. The proteinuria observed in these animals is likely of tubular origin 
Part V: Discussion 
 
60 
 
because histopathology showed tubular necrosis and, further, the increased levels of the 
lysossomal enzyme NAG as tubular nephrotoxicity marker. In our experimental study it 
was observed an increase of the pancreatic enzyme, amylase, in the group OR+LAS. The 
serum amylase can also be elevated in renal failure with a very low creatinine clearance 
(Chawla, 2014). The hypocalcemia observed in these animals may be associated with an 
attack of severe pancreatitis or renal failure (Chawla, 2014).  
Regarding the liver, it is also an organ affected by OR poisoning. Flammer (1980) 
interpreted OR intoxication to consist of hepatorenal syndrome (Flammer, 1980). 
Grzymala (1957) diagnosed jaundice combined with liver swelling and severe liver cell 
necrosis as the primary lesion in the course of intoxication. Autopsy showed liver necrosis 
and interstitial nephritis (Grzymala, 1957). Favre et al. (1976) reported hepatocellular 
damage in humans on the basis of elevated activity of serum glutamatepyruvate-
transaminase (SGPT) and serum glutamate-oxaloacetate-transaminase (SGOT), as well 
as increased plasma bilirubin (Favre et al., 1976). In our study, mild lobular inflammatory 
activity, parenchymal damage, hemorrhage and absence of viable hepatocytes were 
evident in animals treated with OR. In other study, these findings, mainly minor 
hepatocellular vacuolation, was reported (Anantharam et al., 2016). In some animals, foci 
of necrotic cells in the liver were also reported (Schumacher and Hoiland, 1983), as well 
as liver enlargement, fatty degeneration and some necrotic patches in liver cells in 
intoxicated people (Gryzmala, 1965; Grzymala, 1959b). The absence of a LAS-mediated 
protective effect was again observed. Consequently, the animals exposed to OR+LAS had 
livers with an apparent higher volume of lesions.  
In this study, the CK levels were significantly increased in the OR+LAS group, which 
suggests muscle damage. Clinically, CK is used as a marker of myocardial infarction 
(heart attack), rhabdomyolysis (severe muscle breakdown), muscular dystrophy, 
autoimmune myositides and acute renal failure (Chawla, 2014). Hypoalbuminemia is 
common in patients with heart failure (Arques and Ambrosi, 2011). In our study, it was 
observed a decreased albumin in the heart of animals treated with OR+LAS. That being 
said, the serum findings were corroborated by histological observations. It was observed, 
both in the OR and OR+LAS groups, circumscribed areas of ischemic necrosis. A novel 
histopathological finding shown in the present study was the myocardial infarct.   
Dilatation of alveolar capillaries can be observed in lungs of animals treated with OR. 
Lungs of rats administered with OR+LAS exhibited an alveoli accompanied by destruction 
of their walls without obvious fibrosis. This experimental evidence suggests that the 
administration of LAS may aggravate the pulmonary toxicity of OR.  
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Another observation taken from this study was an acute congestion of the red pulp in 
the spleen of both OR and OR+LAS groups, characterized by an increase of red cells 
volume. Neutrophils, plasma cells, and occasionally eosinophils were also present 
throughout the white and red pulps.  In both cases, the toxicity induced for OR was not 
reversed with the administration of LAS. Anantharam et al. reported splenic atrophy, 
characterized by lymphocytolysis in OR-treated mice. The few studies involving rats have 
been focusing on the renal effects of Cortinarius mushrooms ingestion. Other organs, 
such as the lungs, heart and spleen, were not examined histologically (Anantharam et al., 
2016). 
In this study, we could not observe differences on organ to body weight ratio between 
control and treated groups. In other study, intoxicated rats with OR showed a significantly 
greater loss of body weight (Prast and Pfaller, 1988). Anantharam et al. reported a 
statistically significant reduction in organs weight, namely in liver and spleen of mice given 
OR when compared to control group (Anantharam et al., 2016) 
Glutathione is an important antioxidant that plays a major role in protecting cells 
against oxidative stress (Townsend et al., 2003) . GSH depletion may render the cells 
more vulnerable to the deleterious effects of free radicals, increasing their susceptibility 
towards oxidative damage. The cellular balance of GSH and GSSG provides a dynamic 
indicator of oxidative stress. That is, during acute oxidative stress, it is observed a 
decrease in GSH concentration with an associated increase in GSSG concentration 
(Jones, 2002). The most widely used indicator of the redox environment of the cell is the 
ratio of GSH to GSSG (Jones, 2002; Valko et al., 2007). Oxidative stress has also been 
implicated in OR-induced kidney injury (Cantin et al., 1988; Nilsson et al., 2008; Oubrahim 
et al., 1998; Richard et al., 1995). Prast reported, on kidneys exposed to OR, peroxidative 
cell damage, namely the reduced tissue content of glutathione (Prast, 1982). Nilsson et al. 
studied the renal mRNA levels in rats exposed to OR for a set of genes with relevance to 
oxidative stress and antioxidant defense. These investigators reported a strongly 
decrease of the antioxidant defense, namely catalase (CAT), cytoplasmic CuZn-SOD 
(SOD1), and plasma glutathione peroxidase (GPX3), and a significant increase of several 
inflammatory cytokines (IL1b, TGF1β, TNF) (Nilsson et al., 2008). The oxidative stress 
biomarker, GSSG, was markedly increased in the spleens of OR group. As a 
consequence, the ratio GSH/GSSG was decreased. The kidney and liver GSSG levels 
were significantly increased in OR+LAS group. In accordance, the GSH/GSSG ratio 
suffered a significant reduction. In this study, a tendency to an increase in lipid 
peroxidation in spleen, heart and lungs was observed in animals treated with OR+LAS, 
but it did not reach statistical significance. The amount of MDA in kidney was slightly large 
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in OR group but not statistically significant.  In other study, OR applied in vitro to kidney 
homogenate resulted in an enhanced formation of thiobarbituric acid reactive substances 
(largely malondialdeyde) (Prast and Pfaller, 1988). These results confirm that LAS does 
not confer protection against OR-induced oxidative stress. 
In the literature, OR inhibits DNA-depended activity of RNAP II, therefore, the RNA 
levels was used as a measure of its inhibition. Our results showed an inhibition of liver 
GAPDH mRNA transcription elicited by OR. Other study, showed that C. orellanus toxin 
inhibits DNA-depended activity of RNA polymerase II from rat liver and DNA-depended 
activity of RNA polymerase from Escherichia coli (Moser, 1969). 
The present study provides in vivo evidence that LAS does not confer a protection 
against OR induced-toxicity. Indeed, LAS treatment clearly increased the toxicity of OR. It 
is necessary to understand what mechanism is underlying the increased toxic action of 
OR associated with LAS. Experimental study with rats suggested that high-dosed LAS 
increases the risk of toxicity and, in lower doses, the protective effect might be insufficient. 
Dinis-Oliveira and co-authors demonstrated that a LAS dose of 200 mg/kgallowed the full 
survival of PQ+LAS-treated rats, but doses of 100 and 400 mg/Kg  only allowed 60% and 
20% of survival, respectively (Dinis-Oliveira et al., 2009a). According to the literature, the 
toxicity in adults or children attributable to high doses of salicylate results in various 
clinical manifestations depending on plasma concentrations. Mild toxicity occurs for 300–
500 mg/L, moderate toxicity occurs for 500–700 mg/L and severe cases ensue for plasma 
concentrations higher than 750 mg/L (Done, 1960; Proudfoot, 1983). In mild or early 
poisoning, burning in the mouth, lethargy, nausea, vomiting, tinnitus, or dizziness can 
occur. In moderate poisoning all of the above plus tachypnea, hyperpyrexia, sweating, 
dehydration, loss of coordination, and restlessness, can occur (Prescott et al., 1982; 
Proudfoot, 1983). In severe poisonings, hallucinations, stupor, convulsions, cerebral 
edema, oliguria, renal failure, cardiovascular failure, and coma may be seen together with 
metabolic acidosis (Chapman and Proudfoot, 1989; Proudfoot, 1983; Thisted et al., 1987). 
Other studies, to reverse the renal damage induced of OR were performed but without 
effect. Nieminen et al. studied the effect of phenobarbital and phenylbutazone treatment 
on the renal damage induced by the toxic mushroom C.speciosissimus in female rats. The 
effect on renal toxicity in rats by the mushroom extract was investigated after 11 days of 
pretreatment with phenobarbital. It was found that the phenobarbital treatment strongly 
increased the damage induced by C. speciosissimus in the tubules of renal cortex but had 
no effect on the inflammation in the outer medullary zone induced by this toxic mushroom. 
Phenylbutazone treatment had no effect on the renal damage induced by these 
mushroom (Nieminen et al., 1976). The same group, also studied the effect of furosemide 
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on the renal damage induce by the toxic mushroom C. speciosissimus in female rats. It 
was observed that coadministration of furosemide caused marred necrotic changes in the 
tubules of the outer cortical layer, whereas in animals receiving only the mushrooms the 
outer cortex was clear. On the other hand, furosemide had no effect on the degree of 
inflammation. Furosemide clearly increased the nephrotoxicity of C. specisossimus 
(Nieminen et al., 1976).In other study, Nilsson and collaborators studied the effect of 
superoxide dismutase (SOD) on the kidney damage induced by the OR in female rats. 
The treatment with SOD during the 4 days after OR injection led to even further 
decreased renal function. This treatment also increased mortality within the first week 
after OR injection from 0% in the OR group to 33% in the OR + SOD group. This was 
reflected also in the amount of oxidative protein damage in the tubular epithelium, which 
was elevated, compared to the control group, in the OR group and even higher in the OR 
+ SOD group (Nilsson et al., 2008). 
The hindrance of OR toxicity by LAS was established by a 5 months survival study. 
The administration of LAS at 4 h post OR and OR-treated animals resulted in a 100% of 
survival rate. The data demonstrate that the OR dose was not sufficient to cause death. In 
this experimental approach, LAS was administered 4 h after orellanine exposure, seeking 
a more realistic treatment approach, since hospitalization after Cortinarius poisoning 
usually occurs only hours and days after ingestion. 
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6. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
In conclusion, the dosage regimen of LAS used did not promoted protection on 
oxidative stress parameters in the organs of animals treated with OR. There were some 
organs where damage could be observed, namely in kidney, liver, lung, heart and spleen. 
However, with this study, it was given an important step in knowledge on OR-induced 
pathology. Cardiac, splenic and lung injuries are novel findings in rats intoxicated with OR. 
The mechanism for the increase of toxicity by the coadministration of LAS needs 
further studies. It is necessary to test lower doses of LAS, seeing that the dose utilized 
demonstrated to be excessive. Additionally, it is also necessary to test higher doses of OR 
for the purpose of finding the effective dose LD50 in mice, since with our dose all animals 
survived. 
Concerning future perspectives, additional knowledge is necessary to evaluate a long 
term toxicity of OR and the biochemical effects, to take measures suitable to avoid fatal 
consequences, by developing effective therapies to counteract toxic effects. Indeed, it 
would be interesting to find out what degree of kidney, heart, liver, lung and spleen 
damage occurs 14 days after the administration of the OR (latent period). Further 
knowledge of OR toxicokinetics is also necessary. 
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ATTACHEMENTS  
A1 – Kidney biochemistry.  
Evaluated parameter Control OR LAS OR + LAS 
Albumin (g/L) 1.09±0.11 0.75±0.18 0.90±0.063 0.81±0.15 
TP (g/L) 23.05±1.43 23.71±4.50 18.18±0.86 16.97±2.91 
Chol (mg/dL) 43.02±4.92 64.00±27.89 54.86±11.21 26.66±6.28 
HDL (mg/dL) 
LDL (mg/dL) 
6.08±1.80 
58.92±8.44 
9.76±4.29 
61.12±15.72 
8.00 ±1.96 
86.30±11.96 
6.68±1.41 
50.98±6.75 
Glucose (mg/dL) 23.96±4.25 18.38±5.69 21.80±.929.00 17.36±2.91 
Creatinine (mg/dL) 0.08±0.04 0.02±0.02 0.17 ±0.07 0.12±0.07 
UA (mg/dL) 3.58±1.21 2.48±0.97 2.96±1.28 2.30±1.11 
TG (mg/dL) 155.60±58.78 63.75±13.29 101.60±26.84 123.20±33.77 
Amylase (U/L) 118.90±28.57 116.00±2332.00 72.50±14.25 50.42±10.37 
ALAT (U/L) 0.70±0.20 2.36±1.00 1.58±1.48 0.90±0.56 
ASAT (U/L) 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
LDH (U/L) 15.68±3.77 10.75±6.47 14.60±2.97 15.18±3.71 
CK (U/L) 800.70±239.90 1386.00±386.20 1059.00±207.80 1369.00±351.90 
CKMB (U/L) 1372.00±392.00 1465.00±413.40 835.90±290.80 953.10±372.90 
Chloride (mg/dL) 174.10±66.14 50.93±12.11 187.60±32.43 92.90±25.39 
Phos (mg/dL) 9.81±1.82 15.34±3.03 9.30±1.29 16.67±3.10 
Mg (mg/dL) 3.58±0.22 3.52±0.26 3.44±0.26 3.91±0.43 
Ca (mg/dL) 1.03±0.10 1.10±0.040 1.30±0.34 0.80±0.11 
Iron (mg/dL) 1140.00±503.70 517.10±103.20 863.40±219.50 604.00±234.60 
GGT (U/L) 0.00±0.00 30.76±21.21 0.00±0.00 0.00±0.00 
Lactate (mg/dL) 19.80±1.02 13.80±3.96 29.40±3.71 23.80±1.99 
Values are given as mean±SEM (n = 5). 
 
A2 – Liver biochemistry.  
Evaluated parameter Control OR LAS OR + LAS 
Albumin (g/L) 2.92±0.24 2.95±0.14 3.15±0.06 3.02±0.134 
TP (g/L) 137.30±6.14 140.00±11.10 132.50±6.20 128.40±7.985 
Chol (mg/dL) 356.50±26.59 363.50±43.23 365.50±22.36 339.60±15.09 
HDL (mg/dL) 
LDL (mg/dL) 
66.96±7.59 
479.90±54.77 
68.16±6.92 
491.40±63.11 
68.12±20.37 
462.90±48.70 
50.62±13.74 
452.40±48.1 
Glucose (mg/dL) 180.20±19.15 196.00±15.96 189.70±19.78 256.10±33.19 
Creatinine (mg/dL) 0.47±0.29 0.20±0.14 0.36±0.23 0.60±0.2146 
UA (mg/dL) 13.30±3.15 12.98±5.20 13.98±4.16 14.14±5.773 
TG (mg/dL) 515.00±104.10 480.20±85.02 488.70±161.90 425.90±27.09 
Amylase (U/L) 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
ALAT (U/L) 0.92±0.023 0.90±0.00 0.90±0.00 0.90±0.00 
ASAT (U/L) 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
LDH (U/L) 15.68±3.77 10.75±6.47 14.60±2.97 15.18±3.71 
CK (U/L) 83.28±20.53 51.44±16.48 55.32±24.87 32.60±10.23 
CKMB (U/L) 0.00±0.00 16.71±10.99 0.00±0.00 54.98±38.06 
Chloride (mg/dL) 94.68±35.00 71.98±11.73 143.10±27.93 159.30±53.31 
Phos (mg/dL) 0.00±0.00 10.99±6.77 0.00±0.00 0.00±0.00 
Mg (mg/dL) 8.46±0.13 8.28±0.49 7.69±0.22 7.93±0.44 
Ca (mg/dL) 1.86±0.32 2.10±0.24 1.73±0.42 1.78±0.19 
Iron (mg/dL) 3740.00±167.90 5163.00±491 5410.00±646.90 5432.00±497.00 
GGT (U/L) 31.26±5.52 18.32±9.41 32.96±7.07 11.34±3.07 
Lactate (mg/dL) 91.40±6.64 107.20±15.67 92.20±6.40 106.60±11.01 
Values are given as mean±SEM (n = 5). 
 
A3 – Lung biochemistry. 
  
79 
 
Evaluated parameter Control OR LAS OR + LAS 
Albumin (g/L) 0.22±0.09 0.42±0.06 0.13±0.09 0.12±0.07 
TP (g/L) 29.24±6.92 13.68±1.32 11.89±2.36 38.11±13.43 
Chol (mg/dL) 73.24±40.35 21.08±3.12 22.84±5.90 20.23±6.77 
HDL (mg/dL) 
LDL (mg/dL) 
0.80±0.34 
26.12±2.74 
1.48±0.35 
29.66±3.167 
1.80±0.64 
22.92±7.01 
3.12±0.77
#
 
28.16±5.61 
Glucose (mg/dL) 22.14±12.63 7.64±1.22 6.42±0.93 11.28±3.27 
Creatinine (mg/dL) 0.08±0.05 2.71±1.75 0.13 ±0.01 0.01±0.01 
UA (mg/dL) 4.46±0.98 4.42±0.27 3.10±0.33 2.92±0.58 
TG (mg/dL) 110.60±36.36 105.00±20.53 29.96±8.87 74.98±23.33 
Amylase (U/L) 23.58±1.53 13.05±4.85 18.16±7.50 13.60±2.48 
ALAT (U/L) 1.45 ±0.89 3.60±0.94 2.90±0.40 1.65±0.79 
ASAT (U/L) 0.76±0.49 0.00±0.00 0.08±0.08 0.00±0.00 
LDH (U/L) 534.60±182.50 388.90±81.93 783.60±174.70 5778.20±180.50 
CK (U/L) 526.10±228.80 1020.00±466.60 1985.00±388.60 1670.00±484.80 
CKMB (U/L) 1807.00±288.80 1776.00±432.70 1503.00±400.10 1589.00±177.60 
Chloride (mg/dL) 28.33±4.20 65.90±25.39 28.36±11.09 64.76±27.37 
Phos (mg/dL) 29.40±1.24 31.56±0.30 32.03±0.16 31.34±0.42 
Mg (mg/dL) 2.46±0.32 2.29±0.51 2.59±0.42 3.33±0.67 
Ca (mg/dL) 0.83±0.21 1.33±0.46 0.94±0.24 0.68±0.20 
Iron (mg/dL) 399.70±223.90 442.30±252.40 156.80±47.48 145.80±25.84 
GGT (U/L) 0.00±0.00 3.65±3.65 1.80±1.25 1.08±1.08 
Lactate (mg/dL) 13.40±0.40 12.00±0.84 10.80±0.37 10.80±1.11 
Values are given as mean±SEM (n = 5); * p < 0.05 OR vs. Control; # p < 0.05 OR+LAS vs. Control; ᶿ p < 0.05 
OR vs OR+LAS. 
 
A4 – Spleen biochemistry.  
Evaluated parameter Control OR LAS OR + LAS 
Albumin (g/L) 0.14 ±0.05 0.126±0.02821 0.00±0.00 0.03±0.02 
TP (g/L) 7.39±0.88 7.145±0.3835 7.70±0.65 6.03±0.96 
Chol (mg/dL) 10.70±2.15 9.9±1.641 18.18±3.60 17.04±8.01 
HDL (mg/dL) 
LDL (mg/dL) 
1.48±0.30 
9.76±3.21 
2.22±0.4247 
10±1.39 
1.92±0.65 
9.86±2.98 
3.32±1.51 
13.66±4.25 
Glucose (mg/dL) 2.52±1.39 0.46±0.2205 3.64±0.99 3.90±1.80 
Creatinine (mg/dL) 0.01±0.005 0.0125±0.0075 0.03 ±0.026 0.05±0.02 
UA (mg/dL) 1.86±0.82 1.08±0.3929 1.26±0.45 0.94±0.31 
TG (mg/dL) 16.04±6.97 15.04±7.043 25.98±7.64 8.58±4.01 
Amylase (U/L) 122.90±77.36 16.65±12.08 18.40±8.47 11.95±6.08 
ALAT (U/L) 2.30 ±0.43 3.04±1.189 2.78±0.90 2.98±0.92 
ASAT (U/L) 0.23±0.23  0.00±0.00 0.00±0.00 0.00±0.10 
LDH (U/L) 1009.00±197.30 980.80±112.30 735.40±131.20 1083.00±182.10 
CK (U/L) 2600.00±111.00 2571.00±81.91 2196.00±328.30 2184.00±293.20 
CKMB (U/L) 1745.00±217.60 1975.00±171.40 1777.00±247.70 1545.00±301.70 
Chloride (mg/dL) 10.90±3.81 3.6.00±1.217.00 17.64±8.82 5.45±1.04 
Phos (mg/dL) 31.66±0.39 32.04±0.28 31.59±0.64 31.41±0.87 
Mg (mg/dL) 2.72±0.53 3.61±0.70 3.17±0.69 2.53±0.63 
Ca (mg/dL) 1.22±0.21 1.71±0.35 0.72±0.08 1.12±0.29 
Iron (mg/dL) 507.40±234.40 442.70±144.50 282.80±43.13 392.80±86.44 
GGT (U/L) 12.30±3.54 8.90±4.26 9.28±6.87 12.62±4.60 
Lactate (mg/dL) 7.20±0.66 7.25±0.48 8.40±0.51 6.60±0.60 
Values are given as mean±SEM (n = 5) 
 
A5 – Heart biochemistry.  
Evaluated parameter Control OR LAS OR + LAS 
Albumin (g/L) 0.16±0.042 0.10±0.03 0.02±0.01 0.05±0.01 
TP (g/L) 8.21±0.95 9.51±1.81 6.03±1.464 10.22±2.09 
Chol (mg/dL) 8.66±1.76 11.78±4.78 6.66±3.00 11.26±2.64 
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HDL (mg/dL) 
LDL (mg/dL) 
2.84±0.61 
9.34±1.78 
1.74±08 
14.00±3.18 
2.90±1.67 
4.74±2.38 
3.74±0.51 
19.18±6.70 
Glucose (mg/dL) 8.16±1.08 8.66±3.08 5.96±2.72 9.22±2.07 
Creatinine (mg/dL) 0.06±0.04 0.16±0.13 0.002±0.0025 0.09±0.59 
UA (mg/dL) 1.00±0.30 0.43±0.10 1.00±0.34 0.48±0.14 
TG (mg/dL) 44.28±14.15 45.60±16.43 22.72±6.44 16.80±3.47 
Amylase (U/L) 19.88±5.98 8.35±2.44 4.38±2.23 4.23±1.55 
ALAT (U/L) 5.24±2.53 10.42±6.59 0.35±0.21 9.70±4.41 
ASAT (U/L) 1.58 ±1.58 6.36 ±3.96 0.15 ±0.15 0.00±0.00 
LDH (U/L) 12.88±7.30 10.30±3.28 191.8±96.97 10.28±3.49 
CK (U/L) 32.30±7.17 36.46±8.14 193.30±117.70 53.82±15.31 
CKMB (U/L) 1127.00±226.90 1111.00±23 2047.00±336.60 995.00±290.60 
Chloride (mg/dL) 32.88±7.01 23.78±4.74 10.60±3.41 19.60±4.00 
Phos (mg/dL) 28.75±2.879.00 32.93±0.67ᶿ 30.98±0.32 27.58±1.49 
Mg (mg/dL) 2.92±0.42 3.34±0.79 2.73±0.82 2.90±0.67 
Ca (mg/dL) 1.35±0.2489.00 1.45±0.35 0.81±0.13 0.69±0.12 
Iron (mg/dL) 1057.00±511.60 440.00±51.40 204.80±5.91 1298.00±440.10 
GGT (U/L) 22.50±14.19 14.54±6.31 56.56±16.81 10.78±3.19 
Lactate (mg/dL) 19.80±2.35 20.80±2.71 15.40±1.36 19.20±1.91 
Values are given as mean±SEM (n = 5); * p < 0.05 OR vs. Control; # p < 0.05 OR+LAS vs. Control; ᶿ p < 0.05 
OR vs OR+LAS. 
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